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Abstract 
Nuclear hormone receptors (NRs) associate with coregulators to enable complex 
programs of gene expression. The p160 steroid receptor coactivator 2 (SRC-
2/GRIP1) regulates metabolism and cellular processes in a tissue-specific manner by 
enhancing transcription of hormone regulated target genes. The transcriptional 
regulation and metabolic programming imposed by SRC-2 and its partner NRs has 
implications for several pathological processes. Although SRC-2 is known to 
facilitate lipogenesis and survival of prostate cancer cells, its role in breast cancer 
remains unclear. Hepatic ablation of SRC-2 impairs expression of key lipogenic and 
gluconeogenic enzymes, causing fasting hypoglycemia in mice. Previously, it has 
been shown that the cAMP/PKA pathway regulates the protein level of SRC-2. This 
thesis aimed to further investigate the functions of SRC-2 and characterize whether 
upstream regulation of SRC-2 affects its ability to promote expression of metabolic 
target genes. 
 
Paper I elucidates a mechanism by which cellular SRC-2 protein is subject to 
inhibitory upstream regulation by the cAMP/PKA pathway. Here, we showed that the 
cAMP response element-binding protein (CREB) has a key role in this mechanism by 
interacting with and stimulating proteasomal degradation of SRC-2. We demonstrated 
that the CREB basic leucine zipper (bZIP) domain and two functionally independent 
protein domains of SRC-2 (amino acids 347-758 and 1121-1462) are required to 
trigger degradation of SRC-2. Furthermore, overexpression of CREB inhibited the 
ability of SRC-2 to modulate expression of estrogen receptor alpha (ERα) target 
genes. These findings suggest that the previously established inhibitory effect of PKA 
on SRC-2 is executed via a direct interaction between CREB and SRC-2.  
 
Paper II reports that SRC-2 has a crucial function in regulating hepatocellular 
gluconeogenesis. Transcription of gluconeogenic enzymes including the rate-limiting 
glucose 6-phosphatase (G6Pase) is enabled by fasting hormone signaling via the 
cAMP/PKA pathway. Previously, it was demonstrated that SRC-2 liver knock-out 
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mice exhibit fasting hypoglycemia due to reduced G6Pase expression. We validated 
that SRC-2 coactivates the RAR-related orphan receptor alpha (RORα) at the 
proximal G6Pase promoter in HepG2 cells. In line with the findings from the first 
paper, we observed that SRC-2 protein was subject to degradation in presence of the 
PKA catalytic subunit (PKA-Cα). Overexpression of PKA-Cα also reduced 
recruitment of SRC-2 and RNA polymerase II to the G6Pase promoter and rendered 
SRC-2 unable to coactivate RORα. Furthermore, we found that the presence of SRC-
2, via its association with RORα, is required for the transactivational effect of the 
master gluconeogenic regulator PPARG coactivator 1-alpha (PGC-1α) on the G6Pase 
promoter. These results suggest that PKA-mediated degradation of SRC-2 may 
represent an indirect feedback mechanism by which gluconeogenesis is suppressed 
throughout long-term starvation. 
 
Paper III elucidates a novel mechanism by which the anti-diabetic drug metformin 
reprograms hepatocellular metabolism via SRC-2. Tissue from SRC-2 liver knock-
out mouse model is characterized by impaired expression of lipogenic and 
gluconeogenic enzymes. Here, we showed that treatment of cells with metformin is 
accompanied by transcriptional repression of specifically SRC-2. Microarray analysis 
of FaO hepatoma cells treated with metformin revealed an overrepresentation of 
downregulated SRC-2 target genes involved in lipid and cholesterol biosynthesis. 
Promoter analyses confirmed that these genes were also transcriptional targets of the 
lipogenic sterol regulatory element (SRE) binding protein 1 (SREBP-1). 
Transactivation assays demonstrated that SRC-2 is a coactivator of SREBP-1, but not 
SREBP-2, on the fatty acid synthase (FASN) promoter. By repressing SRC-2 
expression, metformin impeded recruitment of SRC-2 and RNA polymerase II to the 
G6Pc promoter and to SREs of SRC-2/SREBP-1 target gene promoters. Furthermore, 
metformin or knock-down of SRC-2 and SREBP-1 reduced hepatocellular fat 
accretion. Accordingly we propose that metformin transcriptionally suppresses 
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1.1 Nuclear Hormone Receptors and Coregulators 
 
1.1.1 Hormone signaling 
Hormones are chemical signal molecules that induce systemic changes in gene 
expression and metabolism of receptive target cells. The specificity of a hormone is 
provided by the interaction with its cognate receptor. Whereas peptide hormones 
generally associate with membrane-bound receptors to trigger different cell signaling 
events, hydrophobic steroid hormones bind to intracellular nuclear hormone 
receptors, rendering them transcriptionally active.  
 
1.1.2 Nuclear hormone receptors 
Nuclear hormone receptors (NRs) are transcription factors that stimulate expression 
of target genes in response to activation by corresponding ligands. The NR 
superfamily is comprised of 48 different receptors in humans [1]. Canonical NRs 
include a DNA binding domain (DBD), ligand binding domain (LDB) and two 
activation function domains (AF1 and AF2) that enables interaction with other 
proteins [2]. Whereas type I NRs, also called steroid hormone receptors, are 
characterized by homodimerization and nuclear import in response to ligand binding, 
type II NRs are natively located in the cell nucleus and heterodimerize with retinoid 
X receptor (RXR) [3]. Several NRs have unknown endogenous ligands and are 
referred to as orphan NRs. Activated NR dimers are recruited to DNA sequences 
termed hormone response elements (HREs), which are composed of two hexameric 
core half-sites [4]. Such HREs position the NRs in close proximity of target gene 
promoters across the genome and facilitate recruitment of chromatin remodeling 
factors, general transcription factors and RNA polymerase II that ultimately enable 
gene transcription. HREs are also frequently located at distal DNA regulatory 
elements called enhancers that, due to the three-dimensional chromatin structure, are 
able to regulate target gene expression [5]. 
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1.1.3 Coregulators  
The ability of NRs to activate a target gene promoter is subject to regulation by post-
translational modifications (PTMs) including phosphorylation, ubiquitylation, 
SUMOylation and interaction with coregulators [6]. Transcriptional coregulators 
(coactivators and corepressors) provide an additional layer of enhancing cellular 
responses to hormone signaling by forming a bridge between DNA-binding 
transcription factors and the basal transcriptional machinery. Coactivators and 
corepressors enhance or repress NR-dependent transcriptional activity, respectively. 
Binding of ligands to type I NRs induces conformational changes that liberate the 
NRs from chaperone sequestration and expose functional protein domains, allowing 
for nuclear import and interaction with transcriptional partner proteins [7]. 
Specifically, agonist ligand binding changes the conformation of the carboxy-
terminal AF2 domain that serves as an interface between NRs and coactivators [3].  
 
1.1.4 Regulation of chromatin by histone modifications 
An important feature of coregulators is to directly or indirectly induce histone 
modifications near target gene promoters [8]. In eukaryote cells, the higher-order 
arrangement of histones and genomic DNA wrapped around nucleosomes is referred 
to as chromatin. The projecting amino-tails of multimeric histones are subject to a 
complex and ever-growing array of covalent PTMs referred to as the epigenetic code. 
In general, histone acetytransferases (HATs) serve to open up chromatin and facilitate 
transcription factor accessibility by neutralizing the positive charge of lysine-rich 
histone tails [9]. Conversely, the activity of histone deacetylases (HDACs) is 
associated with compacting and reduced accessibility of chromatin. Histone tail 
methylation is believed to be more static, and the epigenetic readout from this 
covalent modification is context-dependent and less understood [10]. Patterns and 
combinations of PTMs on histone tail residues form discrete motifs that are 
recognized by cognate domains of chromatin-associated factors [9]. Furthermore, 
methylation of adenine and cytosine residues of the genomic DNA also impacts 
chromatin structure and is associated with transcriptional silencing [11].  
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1.1.5 Steroid receptor coactivators 
The structurally homologous p160 steroid receptor coactivator (SRC) family includes 
the ubiquitously expressed SRC-1 (NCOA1), SRC-2 (NCOA2/GRIP1/TIF2/) and 
SRC-3 (NCOA3/AIB1). The SRCs have three structural protein domains that 
facilitate interactions relating to their functions in transcriptional regulation [12]. The 
amino-terminal basic helix-loop-helix/Per-ARNT-Sim (bHLH/PAS) domain enables 
interaction with several tissue-specific transcription factors and additional 
coactivators, and also contains a nuclear localization signal (NLS) [8]. The central 
region of SRCs constitutes the nuclear receptor interaction domain (NRID) which 
contains three LxxLL (L is leucine and x is any amino acid) motifs. These positively 
charged motifs associate with the AF2 domain of activated NRs. Lastly, the carboxy-
terminal activation domains (AD1 and AD2) allow for interaction with additional 
coactivators and chromatin-modifying enzymes [13]. The AD1 and AD2 domains are 
flanked by a glutamine (Q)-rich region that mediates interaction with NRs [14]. 
When associated with ligand-bound NRs, the SRCs recruit cofactors that facilitate 
transcription of target genes [8]. Several of these factors exhibit histone-modulating 
activity, including coactivator-associated arginine methyltransferase 1 (CARM1), 
protein arginine methyltransferase 1 (PRMT1), p300 and cAMP response element-
binding protein (CREB)-binding protein (CBP) [15]. Additionally, SRC-1 and SRC-3 
exhibit enzymatic HAT activity conferred by a component of the Q-rich protein 
domain [16, 17]. Although the SRCs were initially found to coactivate type I nuclear 
receptors, several novel properties and transcriptional interaction partners have since 
been characterized. 
 
1.1.6 Steroid receptor coactivator 2 (SRC-2) 
The SRC-2 protein exhibits extensive sequence homology with the SRC-1 and SRC-3 
proteins, however, SRC-2 has no intrinsic HAT activity [13]. The function of SRC-2 
is attributed to its functional protein domains (Figure 1). Depending on physiological 
context and tissue, SRC-2 has been shown to coactivate several nuclear receptors 
including androgen receptor (AR), progesterone receptor (PR), glucocorticoid 
receptor (GR), estrogen receptor (ERα), RAR-related orphan receptor alpha (RORα), 
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vitamin D receptor (VDR), farnesoid X receptor (FXR), and the thyroid receptor (TR) 
[13, 18-22]. Some studies have also reported that SRC-2 may act as a conditional 
corepressor on certain promoters [23, 24]. Accordingly the physiological readout of 
SRC-2 function depends on nuclear receptor ligand availability and also which 
hormone signaling pathway it is examined in conjunction with.  
 
 
Figure 1. Functional domains of the SRC-2 protein. The basic helix-loop-helix and 
Per/ARNT/Sim domains (bHLH-PAS), nuclear receptor interaction domain (NRID), 
glutamine-rich (Q) region and activation domains AD1 and AD2 of the 1464 amino 
acids comprising the SRC-2 protein are indicated. Made using Adobe Photoshop. 
 
Genetic ablation studies in mice have been instrumental for elucidating the 
function of SRC-2 in vivo. Current knowledge proposes that SRC-2 exerts important 
functions in development, whole-body energy homeostasis, metabolic regulation, 
oncogenic potential and reproduction [8]. Jeong et al. demonstrated that female SRC-
2-/- knock-out mice are infertile due to impaired placental development [25]. In 2002, 
Picard et al. observed that whole-body ablation of SRC-2 in mice was associated with 
protection from diet-induced obesity, improved insulin sensitivity and enhanced 
adaptive thermogenesis [26]. This study established several important aspects of 
SRC-2 function in adipose tissue. Notably, white adipose tissue from SRC-2 knock-
out mice was characterized by significantly lowered lipid content and primary 
adipocytes from these animals exhibited higher levels of lipolysis and energy 
expenditure compared to wild-type littermates [26]. Picard et al. also demonstrated 
that SRC-2-/- knock-out mice had lower fasting blood glucose levels than the wild-
type animals [26]. In humans, a weak association between obesity and an SRC-2 gene 
single nucleotide polymorphism has been identified [27]. In 2006, Jeong et al. 
presented microarray analyses from tissue of individual SRC-1-/-, SRC-2-/- or SRC-3-/- 
liver knock-out mice [28]. Interestingly, Venn diagram comparison tests revealed that 
there was a surprisingly low amount of common target genes for the three individual 
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SRCs [28]. Transcriptomics analyses confirmed that 245 out of 270 differentially 
expressed genes were upregulated when SRC-1 was knocked out, and only 22 genes 
were downregulated upon ablation of SRC-3 [28]. In contrast, hepatic ablation of 
SRC-2 was accompanied by downregulation 338 genes, several of which represent 
key regulatory enzymes pertaining to glucose, lipid and cholesterol biosynthesis [28].  
These findings were revisited by Chopra et al. in 2008 where it was confirmed 
and demonstrated that ablation of SRC-2-/- in both a whole-body and liver-specific 
manner caused fasting hypoglycemia. Furthermore, knock-out animals exhibited a 
phenotype resembling the glycogen storage disease-1a, characterized by loss-of-
function mutations in the gluconeogenic glucose-6-phosphatase catalytic subunit 
(G6Pc/G6Pase) [19]. The authors provided a mechanism to explain the hypoglycemic 
phenotype by showing that SRC-2 stimulates hepatic G6Pase expression by 
coactivating the nuclear receptor RORα at the G6Pase promoter [19]. An enrichment 
of RORα and SRC-2 was detected by chromatin immunoprecipitation at an atypical 
RORα response element (RORE) sequence in the proximal G6Pase promoter (-54/-49 
relative to G6Pase transcription start site). Interestingly, this particular promoter 
binding site was previously characterized as a crucial regulatory element of G6Pase 
expression: In parallel in 2008, Schilling et al. demonstrated that the ability of PGC-
1α to coactivate the hepatocyte nuclear factor 4-alpha (HNF4α) at the proximal 
mouse G6Pase promoter was abolished upon mutation of the RORE sequence located 
adjacently to the -76/-64 HNF4α binding site [29]. However, these authors were 
unable to confirm the affinity or binding of any one nuclear receptor to this adjacent 
(-54/-49) site. Although the findings from Chopra et al. solved one piece of this 
puzzle, the evident functional relationship between the adjacent HNF4α/PGC-1α and 
RORα/SRC-2 NR-coactivator complexes has remained unexplained (Figure 2).   
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Figure 2. The proximal G6Pase promoter. Previous studies have shown that ablation 
of hepatic SRC-2 causes fasting hypoglycemia in mice by impairing expression of the 
rate-limiting gluconeogenic enzyme G6Pase. SRC-2 coactivates the orphan nuclear 
receptor RORα on the proximal G6Pase promoter. Additionally, the RORα binding 
sequence is required for the transactivational effect of PGC-1α on this promoter. 
Made using Adobe Photoshop. 
 
In 2011, Chopra et al. further pursued the phenotype of whole-body SRC-2 
ablation and reported that SRC-2-/- knock-out mice subjected to overnight fasting also 
exhibited dietary fat malabsorption and reduced plasma triglycerides [22]. This 
defective malabsorption was rescued upon both feeding of the mice with exogenous 
bile acids or adenoviral overexpression of the bile salt export pump (BSEP/ABCB11) 
gene [22]. These findings were reconciled with the evident transcriptional activation 
of the BSEP gene following activation of the AMP-activated protein kinase (AMPK) 
pathway, which is characteristically associated with starvation. The authors also 
showed that AICAR, an AMP-mimicking and thus AMPK-activating compound, 
increased the intrinsic transcriptional activity of SRC-2, and that the AMPK 
holoenzyme phosphorylated SRC-2 in vitro [22]. Furthermore, transfection of HepG2 
cells with the AMPKα2 catalytic subunit increased recruitment of SRC-2 to the FXR 
response element (FXRE) at the BSEP promoter [22].  
The role of SRC-2 in facilitating lipid biosynthesis was emphasized in a 2015 
study conducted by Dasgupta et al., based on the notion that SRC-2 is frequently 
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upregulated in metastatic prostate cancer and thus may represent an oncogene [30]. 
Interestingly, aggressive prostate cancer frequently exhibits a particularly lipid-reliant 
metabolic profile which is granted through dysregulation of the liver X receptors 
(LXR), sterol regulatory element binding proteins (SREBP-1 and SREBP-2) and 
lipogenic enzymes including fatty acid synthase (FASN) and acetyl-CoA carboxylase 
(ACC) [31-35]. The lipid metabolic component and bioenergetic basis of prostate 
malignancy is unique and contrasts the established “Warburg effect” paradigm 
whereby cancer cells primarily rely on anaerobic glucose catabolism and lactate 
fermentation as energy source [36]. Several studies indicate that restricting fatty acid 
availability and synthesis suppresses cancer progression [31]. In line with this logic, 
Daspugta et al. provided data to support a model by which SRC-2 promotes prostate 
cancer progression by contributing to neoplastic fat accretion by coactivating 
SREBP-1 and promoting expression of de novo lipogenic enzymes FASN and 
stearoyl-CoA desaturase (SCD) [30]. It was also shown that phosphorylation of SRC-
2 by the nutrient-activated mammalian target of rapamycin complex 1 (mTORC1) 
was required for SRC-2 to coactivate SREBP-1 [30].   
Whereas SRC-1 and SRC-3 (also known as Amplified in Breast Cancer 1, 
AIB1) unambiguously promote breast cancer, the role of SRC-2 in this pathology is 
not clearly defined [18, 37-39]. Transcriptional target genes of ERα include both 
oncogenes and tumor-suppressor genes [18, 40]. By differentially modulating the 
expression of ERα target genes, SRC-2 may or may not represent an accessory to the 
oncogenic potential of ER-positive (ER+) breast cancer cells [18].  Whereas some 
studies have demonstrated that SRC-2 stimulates cell proliferation, increases cell 
cycle progression and decreases apoptosis in the MCF-7 breast cancer cell model [41, 
42], others have concluded that SRC-2 may have antiproliferative properties in breast 
cancer [18]. Importantly, one article found that the incretin hormone glucagon-like 
peptide 1 (GLP-1), by activating the cAMP/PKA pathway via its cognate G-protein 
coupled receptor, inhibits growth of MCF-7 breast cancer cells [43]. The authors of 
this article suggested a link between reduced serum GLP-1, as observed in type 2 
diabetes, and the correspondingly increased risk of breast cancer.  
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Our group has previously focused on the role of SRC-2 in breast cancer and in 
relation to the cAMP/PKA pathway. Initial findings in our group suggested that the 
cAMP-dependent protein kinase (cAMP/PKA) pathway had an inhibitory effect on 
the ability of SRC-2 to coactivate the steroidogenic factor 1 (SF-1/NR5A1) [44]. 
Subsequent studies in our group elaborated on this finding and demonstrated that 
SRC-2 is recruited to transcriptional target genes of the estrogen receptor (ERα) in 
response to transient stimulation of the cAMP/PKA pathway in the MCF-7 breast 
cancer cell line [45]. However, prolonged or pronounced activation of the 
cAMP/PKA pathway consistently was shown to cause degradation of SRC-2 protein 
[45]. It was also demonstrated that PKA actively regulates SRC-2 by inducing its 
degradation through the ubiquitin-proteasome pathway [46]. In this context, the first 
article of this thesis identifies the cAMP responsive element binding protein (CREB) 
as a key mediator in the mechanism by which the cAMP/PKA pathway targets SRC-2 



















1.2 Liver metabolism 
The liver represents a core metabolic organ that maintains homeostatic levels of 
circulating glucose, fat and nutrients. Glucose is an essential energy substrate for 
several organs and cells in the body and the liver is tasked with providing a steady 
glucose bloodstream supply [48]. After feeding, insulin signaling and high 
intracellular [ATP]/[AMP] ratio stimulate glycolysis and storage of excess glucose as 
hepatic glycogen. During fasting, prevailing glucagon signaling and decreasing 
intracellular [ATP]/[AMP] ratio promote glycogen breakdown coupled with glucose 
export and de novo glucose production via the anabolic process known as 
gluconeogenesis. Glycogen thus serves as a dynamic buffer and rechargeable energy 
source that is replenished after feeding and drained during fasting [49]. When 
glycogen stores are depleted during fasting, hepatic gluconeogenesis represents the 
primary source of glucose for export into the circulation. In terms of metabolic 
coordination, glycolytic and gluconeogenic enzymes are reciprocally regulated by 
both the insulin/glucagon ratio and allosteric modifications caused by the intracellular 
[ATP/AMP] ratio and glucose metabolites [50].  
 
1.2.1 Hepatic gluconeogenesis 
Gluconeogenesis is the metabolic pathway that enables endogenous glucose 
production on demand. In biochemical kinetics, the overall flux of metabolites 
through a pathway of sequential enzymatic modifications is determined by its slowest 
and thus determining step. In the fed state, gluconeogenesis is inhibited due to 
transcriptional suppression of the pathway rate-limiting enzymes 
phosphoenolpyruvate carboxykinase (PEPCK/PCK1) and glucose-6-phosphatase 
catalytic subunit (G6pc/G6Pase). Although PEPCK catalyzes the true rate-limiting 
step of gluconeogenesis, the generation of fructose 6-phosphate by fructose-1,6-
bisphosphatase (F1,6BPase) is also an important regulatory checkpoint [50, 51]. The 
final conversion of glucose-6-phosphate into glucose by G6Pase is also rate-limiting 
in terms of hepatic glucose output, in the sense that only free glucose is eligible for 
export into circulation via the GLUT2 transporter (Figure 3).  
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Figure 3. Enzymatic steps of glycolysis and gluconeogenesis. Glycolysis (purple) is 
the canonical catabolism of glucose into pyruvate. Gluconeogenesis (blue) employs a 
dedicated set of enzymes that enables anabolic de novo glucose production. G6Pase 
catalyzes the final step of both gluconeogenesis and glycogenolysis to generate free 
glucose eligible for export into the circulation via the GLUT2 transporter. PFK1, 
phosphofructokinase-1; PC, pyruvate kinase; PEPCK, phosphoenolpyruvate 
carboxykinase; F1,6BPase, fructose-1,6-bisphosphatase; G6Pase,  glucose-6-
phosphatase. Made using Adobe Photoshop. 
 
Notably, G6Pase also marks the final step of both gluconeogenesis and 
glycogenolysis. During long-term starvation, activity of the gluconeogenic pathway is 
attenuated due to reduced substrate availability. Hepatocytes generate new pyruvate 
from lactic acid and amino acids and this serves to prolong the gluconeogenic flux 
[52]. Adipose tissue responds to starvation with lipolysis of stored triacylglycerol and 
release of non-esterified fatty acids (NEFAs) and glycerol into the circulation [53]. 
Whereas the glycerol can be utilized by hepatocytes, hepatic fatty acid β-oxidation 
does not generate substrates to sustain gluconeogenesis [53]. However, byproducts of 
hepatic β-oxidation include ketone bodies that in turn are exported and serve as 
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metabolic fuel for extrahepatic tissues during starvation [53]. During long-term 
starvation, glucose-dependent tissues including the brain ultimately transition into 
ketone metabolism [54].  
 
1.2.2 The insulin signaling pathway 
Food intake is accompanied release of insulin from pancreatic beta cells to 
compensate for increasing circulating glucose levels. In skeletal muscle and adipose 
tissue, insulin signaling triggers translocation of the glucose transporter GLUT4 from 
the cytoplasm to the cell membrane to facilitate glucose uptake [55]. In the liver, 
insulin signaling regulates several metabolic pathways aimed to store excess fuel as 
glycogen and lipids. Insulin signaling is physiologically associated with glucose 
abundance and thus suppresses gluconeogenesis (Figure 4).  
 
 
Figure 4. Metabolic regulation by the insulin signaling pathway. A central event in 
the insulin pathway is the activation of phosphoinositide 3-kinases (PI3Ks) and 
generation of phosphatidylinositol-3,4,5-triphosphate (PIP3) that serves as docking 
site for the phosphoinositide-dependent kinase 1 (PDK1) and Akt [60]. PDK1 
phosphorylates and activates Akt. Downstream effects of hepatic Akt include 
inhibition of gluconeogenesis. The nutrient-sensitive OGT reversibly modifies 
serine/threonine residues of several components of this pathway and attenuates 
insulin signaling. Reprinted by permission from Macmillan Publishers Ltd: Nature 
[58], 2008. 
 
Binding of insulin or insulin-like growth factor (IGF) to the cognate insulin 
receptor tyrosine kinase causes phosphorylation of the insulin receptor substrates 
IRS1 and IRS2 [56]. Both IRS1 and IRS2 are targets for O-linked β-N-
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acetylglucosamine (O-GlcNAc) transferase (OGT) and it has been shown that 
increased OGT activity attenuates insulin signaling and downstream activation of Akt 
[57]. Furthermore, hepatic overexpression of OGT causes insulin resistance, 
dyslipidemia and impairs expression of insulin target genes [58].  Phosphorylated 
IRS1 serves as a docking site for the Grb2/SOS complex, which in turn activates Ras 
and the mitogen-activated protein kinase (MAPK) signaling pathway [59]. However, 
the main effector of the insulin signaling pathway is the protein kinase B (PKB/Akt). 
Akt phosphorylates and inhibits glycogen synthase 3 (GSK3) and this promotes 
activity of the GSK3 target glycogen synthase (GS). Akt is known to trigger GLUT4 
vesicle mobilization and stimulate protein synthesis and lipogenesis by directly 
activating mTORC1 and SREBP1 [61, 62]. Hepatic insulin signaling also leads to 
phosphorylation of CRTC2/TORC2 at Ser171, which thus disrupts its ability to 
coactivate CREB and stimulate expression of PGC-1α [63].  
 
1.2.3 The cAMP/PKA signaling pathway 
Fasting is accompanied by release of glucagon from pancreatic alpha cells to 
compensate for decreasing circulating glucose levels. Glucagon binding to the 
glucagon receptor, a G protein-coupled receptor, activates adenylyl cyclase and 
generation of cAMP that in turn binds to and liberates the regulatory subunit from the 
cAMP protein kinase (PKA) holoenzyme which causes dimerization of the catalytic 
alpha subunits (PKA-Cα) [64]. Adrenaline also activates the cAMP/PKA pathway 
with similar downstream consequences [65]. Activated PKA phosphorylates several 
regulatory enzymes and transcription factors in order to initiate a metabolic program 
designed to counteract a transient and systemic energy demand. In particular, this 
entails activation of hepatic glycogenolysis and gluconeogenesis. 
In the absence of cAMP/PKA signaling, the bifunctional enzyme 
phosphofructokinase-2 (PFK2) favors generation of fructose 2,6-bisphosphate, and 
this metabolite allosterically inhibits the activity of key regulatory gluconeogenic 
enzymes [50]. When phosphorylated by PKA, the PFK2 phosphatase activity is 
stimulated and the resulting removal of fructose 2,6-bisphosphate restores the activity 
of gluconeogenic enzymes, in particular F1,6BPase [50, 66].     
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 PKA stimulates transcription of several metabolic target genes characterized 
by promoter cAMP response elements (CRE) by activating CRE-binding protein 
(CREB) [67]. In addition to PKA-mediated phosphorylation of CREB at Ser133, 
interaction with both CREB regulated transcription coactivator 2 (CRTC2/TORC2) 
and the coactivator CREB binding protein (CBP) is crucial to inducing effective 
target gene transcription [68]. A key transcriptional target of hepatic CREB is the 
master gluconeogenic coactivator PGC-1α. Notably, insulin signaling stimulates 
activity of salt-inducible kinase 2 (SIK2) which in turn renders CRTC2 inactive [69]. 
The CREB complex is only transcriptionally active in the absence of insulin [63]. 
Thus, insulin and fasting hormone pathways converge to regulate PGC-1α at the 
transcriptional level (Figure 5). Hepatic PGC-1α coactivates both HNF4α and 
FOXO1 to stimulate expression of target gluconeogenic genes, and it has been shown 
that PGC-1α knock-out mice exhibit fasting hypoglycemia [70]. 
 
Figure 5. Control of coactivators is central to the regulation of gluconeogenesis. 
The CREB coactivators CRTC2 and CBP are subject to inhibitory PTMs induced by 
the insulin signaling pathway. As a result, transcription of the target gene PGC-1α 
proceeds only in the absence of insulin. In turn, PGC-1α enables transcription of rate-
limiting gluconeogenic enzymes. Reprinted by permission from Macmillan 
Publishers Ltd: Nature [71], 2011.       
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1.2.4 The AMPK signaling pathway 
As starvation progresses, hepatic gluconeogenesis diminishes partly due to substrate 
availability. Metabolic stress and prolonged glucose deprivation cripple ATP 
production and result in an increased intracellular [AMP]/[ATP] ratio. This condition 
triggers activation of the AMP-activated protein kinase (AMPK), a metabolic master 
regulator. The AMPK holoenzyme is a heterotrimeric complex consisting of a 
catalytic α subunit and regulatory subunits β and γ. Binding of AMP activates AMPK 
allosterically and enables phosphorylation of Thr172 of the AMPKα subunit by the 
upstream liver kinase B1 (LKB1) [72]. The overall mandate of the AMPK pathway is 
to restore energy balance by stimulating catabolic pathways to generate energy while 
shutting down anabolic pathways to save energy [73]. By phosphorylating key 
regulatory enzymes, AMPK promotes glycolysis, fatty acid beta-oxidation, GLUT4 
translocation while inhibiting gluconeogenesis, lipogenesis, proliferation and 
biosynthesis of protein and cholesterol (Figure 6). 
Notably, AMPK phosphorylates and inactivates the CREB coactivator 
CRTC2/TORC2 to inhibit gluconeogenic gene expression [74]. AMPK-mediated 
phosphorylation of hepatic SREBP-1 suppresses its proteolytic processing, nuclear 
translocation and lipogenic target gene expression [75]. AMPK has also been found 
to inhibit SREBP-1 at the transcriptional level, by inhibiting liver X receptor (LXR) 
ligand production and possible also LXR activity [76]. The LXR nuclear receptors 
are activated by cholesterol derivate ligands and stimulate hepatic lipogenesis [77]. 
Conversely, AMPK phosphorylates acetyl-CoA carboxylase (ACC), an important 
enzyme involved in de novo lipogenesis [78]. AMPK has also been shown to 
phosphorylate and inactivate the carbohydrate-responsive element-binding protein 
(ChREBP/MLXIPL) [79, 80].  
 The AMP analog compound AICAR has been used experimentally to stimulate 
AMPK activity. By interacting with the regulatory AMPK γ-subunit in the same 
manner as conventional AMP, AICAR manipulates the perceived [AMP]/[ATP] ratio 
and triggers the energy sensor rheostat AMPK [81]. 
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Figure 6. The AMPK pathway regulates hepatocellular energy balance. Cellular 
energy depletion triggers AMPK activation. The AMPK metabolic reprogramming is 
mediated by phosphorylation of several key downstream regulatory enzymes and 
transcription factors. Illustration reproduced courtesy of Cell Signaling Technology, 
Inc., 2015. 
 
1.2.6 Regulation of hepatic lipid metabolism 
De novo anabolism of lipids from acetyl-CoA is referred to as lipogenesis. The initial 
substrate modification is catalyzed by acetyl-CoA carboxylase (ACC) and generates 
malonyl-CoA, and this is considered to be the rate-limiting step in lipogenesis [82]. 
Fatty acid synthase (FASN) catalyzes iterative incorporation of acetyl-CoA to 
generate long-chain fatty acids at the cost of NADPH. FASN exhibits seven different 
catalytic sites in addition to including an acyl carrier protein [83]. Since FASN is 
regulated at the transcriptional level, there is now consensus that it represents a 
situational rate-limiting enzyme of the lipogenic pathway [82].  
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Regulation of lipogenesis is central to maintaining energy homeostasis, and 
this is largely mediated by nuclear receptors in response to upstream intracellular 
signaling. In the liver, insulin signaling triggers the lipogenic transcription factor 
triangle consisting of LXR, ChREBP and SREBP-1c [84]. LXRs are activated by 
oxysterols and promote lipogenesis at the transcriptional level by dimerizing with 
Retinoid X receptor (RXR) [85]. LXRs are also activated in response to insulin 
signaling and the insulin-dependent O-GlcNAc post-translational modification [86, 
87]. Target genes of LXR include lipogenic enzymes as well as SREBP-1c and 
ChREBP [88, 89]. Lipogenic genes are also regulated by glucose and, in response to 
high glucose concentrations, ChREBP binds carbohydrate response elements to 
activate transcription of target genes including G6Pase, FASN and ACC [90, 91].  
SREBP-1 is regarded as a master lipogenic regulator and its expression is 
reduced by fasting due to suppression of insulin and increased glucagon levels [92]. 
Downregulation of SREBP-1c also occurs in response to treatment with metformin 
and the AMPK-stimulating compound AICAR [93]. Conversely, insulin signaling 
associated with refeeding stimulates SREBP-1 activity [94]. SREBP-1c is the 
predominant hepatic SREBP isoform and stimulates expression of lipogenic enzymes 
in response to its own upregulation and maturing post-translational processing by the 
insulin signaling pathway [95]. Target genes of SREBP-1c are characterized by a 
sterol regulatory element (SRE) binding sequence, and this is found in the promoters 
of genes encoding enzymes that catalyze various steps in fatty acid and triglyceride 
synthesis [95]. SREs are also frequently found in promoters of enzymes pertaining to 
cholesterol biosynthesis. Notably, SREBP-1a and especially SREBP-2 appear to 
control expression of cholesterol related genes to a larger extent than SREBP-1c [92, 
96]. The inactive precursor SREBP-1 is tethered to the endoplasmic reticulum 
membrane, and its proteolytic processing is mediated by the SREBP cleavage-
activating protein (SCAP) and two site-specific proteases (S1P and S2P) [92]. The 
processing and nuclear import of SREBP is enabled by combination of insulin 




1.3 Type 2 diabetes 
The recent emergence of a global obesity epidemic characterized by a sedentary 
lifestyle, excessive calorie intake and resulting adiposity has dramatically increased 
the incidence of lifestyle diseases including non-insulin-dependent type 2 diabetes 
(T2D) [97, 98]. The Norwegian Diabetes Association have estimated that 350 000 
Norwegians have T2D, and that this form of diabetes accounts for more than 90% of 
diabetic patients [99]. Although the pathogenesis remains unclear and attributable to 
environmental factors, genome-wide association studies have explored the genetic 
components of T2D and shown that this is a polygenic disease with several 
implicated “diabetogenes” that predispose to both initiation and progression of 
disease [100, 101].  Essentially, T2D is characterized by insufficient pancreatic 
insulin production coupled with systemically impaired insulin signaling, and this is 
the basis for insulin resistance. The following definition is proposed by Lebovitz 
[102]: “Insulin resistance is defined clinically as the inability of a known quantity of 
exogenous or endogenous insulin to increase glucose uptake and utilization in an 
individual as much as it does in a normal population”.  
Notably, insulin resistance also negates the inhibitory effect of insulin on 
hepatic glucose production. Insulin inhibits hepatic gluconeogenesis indirectly by 
restricting pancreatic α-cell glucagon secretion and also by limiting adipocyte 
lipolysis that generates gluconeogenic precursors [103]. Furthermore, insulin 
signaling in hepatocytes directly restricts gluconeogenesis by several mechanisms 
including transcriptional suppression of PGC-1α and its target gluconeogenic genes 
by activation of PI3K/Akt [104, 105]. Insulin resistance renders insulin signaling 
unable to control the gluconeogenic enzymes and this contributes to increased hepatic 
glucose production and hyperglycemia [105]. Pharmacological management of T2D 
is required to mitigate the adverse effects of chronic hyperglycemia including, but not 
limited to retinopathy, neuropathy, nephropathy, atherosclerosis, coronary heart 
disease, glycation product formation and stroke [106, 107].  





Herbal medicine in the medieval Europe employed extract from the French lilac 
(Galega officinalis) to treat urinary symptoms that today are attributed to diabetes 
[108]. A guanidine compound was subsequently characterized as the active 
ingredient, and pharmacological optimization of this original plant-derived molecule 
resulted in the synthetic biguanide drug that today is known by its generic name 
metformin [108].  Clinically, metformin ameliorates hyperglycemia without causing 
hypoglycemia or weight gain [109]. Since the 1970s, metformin has generally been 
the mainstay treatment for T2D and currently it marks the most widely used 
antidiabetic drug worldwide [110]. Little progress was made to elucidate the 
mechanism by which metformin exerted its effects until 2001, when Zhou and co-
workers established that administration of metformin caused activation of the 
canonical AMPK pathway in hepatocytes [111]. Although an explosion of subsequent 
publications has greatly increased our knowledge of how metformin causes metabolic 
reprogramming of target cells, its exact mechanisms of action remain elusive.  
It is thought that accumulation of metformin in the mitochondrial matrix 
disrupts the proton gradient and transiently inhibits the electron transport respiratory 
chain complex I, thus indirectly leading to increased intracellular [AMP]/[ATP] ratio 
and successive activation of LKB1 and the energy-sensing AMPK [112-114]. In 
accordance with the known downstream effects of the AMPK pathway, several 
studies have shown that metformin inhibits gluconeogenesis and biosynthesis of 
lipids and cholesterol [109, 111, 112, 115, 116]. A recent study by Shulman and co-
workers showed that metformin non-competitively and acutely inhibits the 
mitochondrial redox shuttle enzyme glycerophosphate dehydrogenase, and that the 
resultant modulation of cytosolic and mitochondrial redox states per se reduced 
hepatic glucose production in rats [117]. Studies have reported that metformin retains 
inhibition of gluconeogenesis and the mTOR pathway in absence of AMPK [109, 
118, 119]. Thus, the precise mechanisms by which metformin modulates hepatic 
metabolism remains elusive. 
As discussed previously, the pleiotropic AMPK pathway regulates cellular 
energy balance and metabolism in part by inhibiting the mTOR pathway [112]. In this 
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regard, metformin may exhibit antineoplastic properties [110, 111]. Preliminary 
studies have demonstrated that metformin treatment was associated with decreased 





































1.4.1 Cell lines 
All cell lines were purchased from the American Type Culture Collection 
(ATTC) and cultured in line with the recommended instructions. Cultures were 
checked for mycoplasma infection prior to use. 
For paper I, the COS-1 African green monkey kidney fibroblast cell line was 
used for transient plasmid overexpression experiments due to high transfection 
efficiency using an established protocol [45]. Stable knock-down of SRC-2/GRIP1 in 
the breast cancer adenocarcinoma MCF-7 cell line was obtained by lentiviral 
integration of a SRC-2 short hairpin RNA (shRNA). A corresponding empty vector 
(control shRNA) was introduced for the purpose of obtaining a control MCF-7 cell 
line. 
For papers II and III, we employed the hepatocellular cell models to elucidate 
mechanisms by which SRC-2 regulates hepatic metabolism. FaO and HepG2 cell 
lines are derived from rat and human hepatomas, respectively, and represent well 
established cell lines for studies of hepatocellular metabolism. Both of these cell lines 
are insulin-sensitive and exhibit gluconeogenic potential. Due to high transfection 
efficiency, HepG2 cells were preferentially employed for transient plasmid 
overexpression assays.  
 
1.4.2 Microarray analysis 
Agilent biochip microarray was performed to characterize the effect of metformin on 
the combined transcriptome of FaO cells in response to treatment with metformin. 
Biological triplicates of cells treated with water (control vehicle) or metformin (5 
mM) for 24 hours were processed for RNA purification and RNA integrity number 
(RIN) analysis. The microarray analysis was performed at the Norwegian Microarray 
Consortium core facility at the University of Bergen. The parallel quantification of a 
large array of mRNA transcripts is based on hybridization of the sample mRNA, 
cRNA or cDNA with complementary sequences across thousands of ‘spots’ of a pre-
arranged microarray slide [122]. When the slide is excited with laser, the level of 
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hybridization for individual genes can be detected due to the presence of fluorescent 
dyes [122].  
 Digital data output from the microarray was processed using J-Express gene 
expression analysis software. A significance analysis of microarrays (SAM) was 
performed to analyze differential gene expression between control and metformin 
treated cells. SAM provides an algorithm that calculates the significance of gene 
expression through multiple comparisons, taking into account both the actual and 
expected signal intensity associated with each gene. Following the SAM analysis, 
genes are attributed a score, Delta [i], which is based on both the fold change and 
difference between observed and expected statistical strength. Permutations of the 
data set allows for determination of the false discovery rate (FDR), a measure of the 
expected rate of false positives (type I errors) when conducting multiple comparison 
[123]. The local FDR associated with a gene reflects the probability of that gene 
being a false positive [124]. Some studies prefer to present significance of microarray 
results using the q-value, which is an FDR-adjusted p-value. Refinement of the SAM 
data is achieved by implementing lowest acceptable cut-off points in terms of both 
absolute gene fold change (FC) and FDR. The set of differentially expressed genes 
that meet these validation criteria is next subject to a gene ontology bioinformatic 
analysis where information pertaining to functional classification is assigned to each 
gene. In accordance with the established instructions [125], we employed the 
PANTHER database (pantherdb.org) to generate a comprehensible and functional 
overview of statistically overrepresented gene categories. Since microarrays may not 
accurately provide data at the single gene level, qPCR validation was performed with 
respect to genes of further interest. 
 
1.4.3 Quantitative polymerase chain reaction (qPCR) 
In all three papers, qPCR was used to measure target gene expression in terms mRNA 
level. Briefly, total RNA was isolated from sample cells and reverse-transcribed into 
cDNA prior to real-time qPCR analysis. Primers were designed in silico to amplify 
complementary regions of the target gene mRNA. We also validated primer 
efficiencies and melting temperature curves. RT-qPCR was run on a Roche 
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LightCycler 480 using SYBR I green dye that binds specifically to dsDNA, emitting 
fluorescence when excited by light after each qPCR cycle. In all experiments, the 
mRNA level of the target gene of interest was normalized to that of an internal 
reference gene. Depending on which gene exhibited the most stable mRNA level in 
response to experimental conditions, we employed glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), TATA-binding protein (TBP) or ribosomal protein L4 
(RPL4) as reference genes. Notably, we observed that the glycolytic enzyme GAPDH 
was downregulated at the transcriptional level by metformin treatment, and 
consequently RPL4 was used as reference gene instead. The relative mRNA level of 
the gene of interest compared to reference gene was calculated using the delta-delta 
Ct method, assuming parallel primer efficiencies of 2.0 per PCR cycle. This 
calculation subtracts the mean [Ct (target gene)] – [Ct (reference gene)] for the 
control treatment and relates the resulting difference to that of equivalently calculated 
samples where cells were subjected to treatment. Thus if the normalizer sample 
exhibits Ct target gene = 25 and Ct reference gene = 25 (ΔCt = 0), and a treatment 
sample exhibits Ct target gene = 26 and Ct reference gene = 25 (ΔCt = 1), this returns 
a ΔΔCt = 1.  Since the number of qPCR cycles (n) is exponentially inversely related 
to the original amplicon amount and amplifies amplicons at an projected efficiency of 
2.0, the relative amount of mRNA is can be expressed as 2-n. In the above example,  
2-1 = 0.5, suggesting that expression of the target gene was reduced by 50 % relative 
to the control treatment. Ct values exceeding 35 PCR cycles were considered invalid. 
 
1.4.4 Chromatin immunoprecipitation (ChIP) 
ChIP allows for quantitative detection of transcription factors and associated 
coregulators on genomic promoters of interest [126]. Functional ChIP assays were 
performed to assay changes in recruitment (enrichment) resulting from distinctive 
experimental conditions. For this purpose, we used the Magna EZ-ChIP kit in 
accordance with the manufacturer’s instructions. Briefly, cells were treated as 
indicated and fixed with formaldehyde prior to lysis and sonication of lysate. 
Sonication was optimized to shear genomic DNA into 200-1000 base pair fragments, 
as verified by electrophoretic agarose gel. In conjunction with magnetic protein A/G 
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beads, sonicated lysate samples were incubated overnight with positive control (anti-
RNA polymerase II), background noise negative control (normal IgG) or target (anti-
SRC-2) antibodies. Eluted DNA was analyzed by qPCR using primers to amplify 
specific genomic promoter regions. The recent ChIP-sequencing technology is based 
on these same principles, but retrieves far more data with the combined sequencing of 
all eluted DNA fragments. Notably, good results from ChIP assays greatly depend on 
the specific interaction between antibody and target antigen. In paper III, failure to 
immunoprecipitate the rat SRC-2 antigen in FaO cells with three separate ChIP-grade 
antibodies prompted us to employ human HepG2 cells for this purpose instead. The 
resolution of ChIP assay for “footprinting” of a target transcription factor is limited 
by the chromatin fragment sizes that are normally distributed around 500 base pairs.   
 
1.4.5 Electrophoretic mobility shift assay (EMSA) 
Affinity and binding of transcription factors to cognate DNA recognition sequences 
can be verified in vitro using EMSA. Affinity of the nuclear receptor RORα to its 
consensus RORα response element (RORE) recognition sequence is well established 
[127, 128]. In paper II, we demonstrate binding of RORα to an atypical RORE in the 
proximal mouse G6Pase promoter has not been previously shown by EMSA. Briefly, 
purified V5-tagged RORα protein was incubated with hot, radioactively labelled 
positive control probe (consensus RORE) or probe of interest (G6Pase RORE). 
Protein-DNA complexes were separated by gel electrophoresis and visualized by 
autoradiography. Parallel addition of excess cold probes and antibody-mediated 




All papers included in this thesis employed small interfering RNA (siRNA) to knock 
down genes of interest in cell cultures. It is of crucial importance to optimize the 
knock-down protocol and verify that the siRNA significantly and specifically 
downregulates the gene of interest. Optimization of our protocol suggested that 
knock-down at both mRNA and protein level peaked when cells were incubated with 
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siRNA for 72 hours prior to analysis. This relatively large window of time allows for 
prolonged silencing of the gene of interest while the existing target protein 
component is depleted during several half-life cycles. In all experiments, transfection 
with non-targeting (NT) siRNA was included as control. Although siRNA is inferior 
to knock-down and CRISPR genomic approaches, it represents a cost-efficient way to 































The aims of this thesis were to elucidate novel mechanisms by which transcriptional 
and post-translational regulation of SRC-2 determines hepatocellular metabolism. 
 
The specific aims of this thesis were: 
 
Paper I 
To elucidate the molecular events and components that execute the previously 
identified PKA-mediated degradation of SRC-2 protein. 
 
Paper II 
To determine whether the cAMP/PKA pathway regulates gluconeogenic G6Pase 
expression via RORα and its coactivator SRC-2. 
 
Paper III 
To determine whether metformin transcriptionally inhibits hepatocellular glucose, 




















In this study we demonstrated that the inhibitory effect of PKA on SRC-2 protein 
level is mediated by the transcription factor CREB. Overexpression of CREB reduced 
SRC-2 protein level, intrinsic transactivation activity and ability to coactivate ERα. 
Degradation of SRC-2 occurred regardless of CREB Ser-133 phosphorylation status, 
and was abrogated in the presence of the proteasome inhibitor MG132. The ability of 
CREB to target SRC-2 for degradation was mediated by a direct protein-protein 
interaction between the CREB bZIP domain and two functionally independent protein 
domains of SRC-2 (amino acids 347-758 and 1121-1462). Interestingly, PKA-
stimulated degradation of SRC-2 was accompanied by changes in gene expression of 
several ERα target genes in MCF-7 breast cancer cells.  
 
Paper II 
In this study we explored the function of SRC-2 in regulating expression of the 
gluconeogenic enzyme G6Pase. SRC-2 stimulated G6Pase expression by coactivating 
RORα at an atypical RORE located on the proximal G6Pase promoter. We observed 
that the activity of this RORα/SRC-2 complex was markedly inhibited by PKA 
activity due to proteasomal degradation of SRC-2. Binding of RORα to the atypical 
G6Pase RORE was not affected by PKA activity, as confirmed by EMSA. Potent 
activation of PKA reduced recruitment of SRC-2 and RNA polymerase II to the 
G6Pase promoter. Using the synthetic RORα ligand SR1001 to disrupt coactivator 
recruitment, we found that SRC-2 is required for the transactivational effect of PGC-
1α on the G6Pase promoter. This observation was confirmed by siRNA and 
transactivation assays using G6Pase promoter constructs with mutated nuclear 
receptor binding sites. PGC-1α is a coactivator of HNF4α, which is recruited to a 
binding site adjacent to the G6Pase RORE. Our findings may imply that SRC-2 is 




In this study we demonstrated that the anti-diabetic drug metformin represses 
expression of SRC-2 in a dose-dependent manner. Microarray analysis of FaO 
hepatoma cells revealed that rate-limiting enzymes involved in gluconeogenesis 
(G6pc) and biosynthesis of lipids (Fasn) and cholesterol (Hmgcr, Hmgcs1) were 
downregulated by metformin. These genes were validated as SRC-2 target genes and 
several of the corresponding gene promoters were characterized by sterol regulatory 
elements. Transactivation experiments confirmed that SRC-2 acts as a coactivator for 
SREBP-1, but not SREBP-2. We also found that recruitment of SRC-2 and RNA 
polymerase II to target gene promoters was markedly reduced in presence of 
metformin. Treatment of cells with metformin or knock-down of SRC-2 and SREBP-























4. General discussion 
 
Nuclear receptors recruit transcriptional coregulators that enhance or repress 
expression of hormonally regulated target genes. The stimulatory and inhibitory 
properties of coactivators and corepressors, respectively, provide an additional layer 
of transcriptional regulation and fine-tuning of cellular metabolism [129]. While 
nuclear receptors have become a paradigm for therapeutic targeting, the potential for 
pharmacological modulation of coregulators remains largely unexplored [130]. 
Pertaining to the p160 steroid receptor coactivator family, SRC-2 is widely 
recognized as a coactivator of several nuclear receptors. Compared to wild type 
littermates, SRC-2 knock-out mice are phenotypically characterized by (i) fasting 
hypoglycemia and glycogen immobilization due to reduced expression of hepatic 
G6Pase [19], (ii) reduced expression of hepatic enzymes pertaining to biosynthesis of 
lipids and cholesterol [28] and (iii) protection from both obesity and insulin resistance 
when fed a high-fat diet [22, 26]. These clear phenotypic traits point to SRC-2 as a 
mediator of anabolic pathways (i.e. energy storage) in both liver and adipose tissue, 
with implications for whole-body physiology. In humans, single nucleotide 
polymorphisms of the SRC-2 may be linked to obesity [27]. The above studies and 
observations warrant additional knowledge of how SRC-2 is regulated to affect cell 
metabolism. Importantly, identification of relevant cell signaling pathways and novel 
DNA-binding molecular interaction partners is a key to elucidating the mechanisms 
by which SRC-2 regulates metabolism in a dynamic and tissue-specific manner.  
 
4.1 Transcriptional regulation of SRC-2             
Transcriptional regulation can be defined as the net rate by which an array of 
transcription factors and coregulators facilitate the ability of RNA polymerase to 
transcribe mRNA from a target gene promoter.  In paper III we demonstrated that the 
anti-diabetic drug metformin dose-dependently represses hepatocellular expression of 
SRC-2, whereas SRC-1 and SRC-3 were not affected. In light of the known 
physiological functions of SRC-2, this finding is innately reconcilable with the ability 
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of metformin to inhibit hepatic gluconeogenesis and lipogenesis. Since SRC-2 binds 
to and stimulates transcription of its own promoter [131], our findings may imply that 
metformin breaks this autonomous self-stimulating loop. We also observed that 
treatment of cells with metformin drastically downregulated the inflammatory 
transcription factor EGR1, which previously has been identified as an SRC-2 target 
gene [18]. The inhibitory effect of metformin on EGR1 expression in monocytes has 
been established previously [132]. A study conducted by Zhang et al. demonstrated 
that EGR1 knock-out mice were protected from diet-induced obesity, fatty liver and 
insulin resistance [133]. Interestingly, these phenotypic traits are remarkably 
overlapping with that observed in SRC-2 knock-out animals. Bioinformatic analysis 
of the SRC-2 promoter revealed the presence of an EGR1 binding site. It may thus be 
possible that EGR1 stimulates expression of SRC-2, and vice versa, in a feed-forward 
loop. Furthermore, SRC-2 by promoting lipogenesis and EGR1 by unknown 
mechanisms are both unequivocally implicated in facilitating survival of prostate 
cancer cells in an androgen-depleted environment [30, 134, 135]. Interestingly, 
administration of metformin reduced the mortality after diagnosis in prostate cancer 
patients [136]. Generating data to support the hypothesis concerning the possible 
mutual transcriptional association of SRC-2 and EGR1 was unfortunately outside the 
scope of paper III, and will consequently be subject to a possible future investigation. 
In contrast to the inhibitory effect of metformin on SRC-2 expression described in 
paper III, activation of the cAMP/PKA pathway in paper II did not affect SRC-2 
mRNA levels. 
 
4.2 Post-translational regulation of SRC-2 
The SRCs are subject to regulation by intracellular signaling, thus modulating the 
ability of associated nuclear receptors to promote transcription of target genes [137]. 
Although several PTMs have been characterized to influence the function and activity 
of SRC-3, much less is known about PTMs affecting parameters of SRC-2 function. 
In paper I, we described a previously undefined mechanism by which prolonged 
activation of the cAMP/PKA pathway stimulates proteasomal degradation of 
ubiquitylated SRC-2. Physiologically, this work relates to hormonal activation of the 
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cAMP/PKA pathway but with no particular hormone in mind. Others have shown 
that the incretin hormone GLP-1 negatively affects the growth of breast cancer cells 
by activating the cAMP/PKA pathway [138]. Previously, it was shown that PKA 
inhibited SRC-2 coactivator function by targeting SRC-2 for destruction via the 
ubiquitin-proteasome pathway [46]. The missing components of this mechanism were 
addressed in paper I and include: characterization of CREB as an executing factor of 
the PKA-mediated degradation of SRC-2; confirmation of a molecular interaction 
between CREB and SRC-2 and the corresponding mapping of involved protein 
domains of CREB and SRC-2, respectively. Importantly, we were also able to 
demonstrate that the mRNA levels of SRC-2 target genes were downregulated as a 
result of the described CREB-induced degradation of SRC-2. Although this finding 
from paper I was primarily thought to be relevant in terms of breast cancer and ERα 
coactivation, we decided to investigate whether the same basic mechanism, by which 
the cAMP/PKA pathway inhibits expression of SRC-2 target genes, may also be 
relevant with regard to physiological events in the liver. The implication of PKA-
mediated degradation of SRC-2 in context of hepatocellular regulation of 
gluconeogenesis was therefore investigated in paper II. Here, we demonstrated that 
potent PKA activity is accompanied by proteasomal degradation of SRC-2 and 
inability of SRC-2 to coactivate its partner nuclear receptor RORα on the proximal 
G6Pase promoter. Furthermore, the master gluconeogenic coactivator PGC-1α was 
unable to transactivate the G6Pase promoter in the absence of RORα and/or SRC-2. 
This observation may be explained by the observation that PGC-1α is known to 
coactivate HNF4α at an adjacent binding site, 20 base pairs upstream of the relevant 
RORE, on the G6Pase promoter. In paper II we demonstrate direct binding of RORα 
to this RORE by EMSA. Although this particular RORE has been previously reported 
to greatly affect the ability PGC-1α to transactivate the G6Pase promoter, its atypical 
nucleotide sequence occluded its pertinence to RORα [29]. We observed that binding 
of RORα to its consensus RORE was markedly stronger than to that of the atypical 
G6Pase RORE. However, EMSA and transactivation assays unequivocally 
demonstrated the affinity of RORα to both binding sites.   
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Dipeptidyl peptidase-IV (DPP-IV) inhibitors attenuate the degradation of 
incretin hormones including GLP-1, and these promising drugs have recently been 
introduced as treatment for hyperglycemia associated with type 2 diabetes [139]. By 
inhibiting the degradation of GLP-1, this class of drugs increases pancreatic β-cell 
insulin secretion and inhibit α-cell glucagon secretion to indirectly reduce hepatic 
glucose production [140]. Several studies have also shown that DPP-IV inhibitors 
reverse the progression of NAFLD by directly affecting hepatocyte metabolism [141, 
142]. The mechanisms by which DPP-IV inhibitors directly inhibit hepatic 
gluconeogenesis and lipogenesis remain unknown. Interestingly, it has been shown 
that hepatocytes express the GLP-1 receptor, and that PKA is activated in response to 
stimulation of hepatocytes with GLP-1 [143, 144]. It is thus likely that DPP-IV 
inhibitors prolong the postprandial surges of GLP-1-mediated cAMP/PKA pathway 
activity in hepatocytes. This may be related to our findings that prolonged PKA 
activity triggers degradation of hepatocellular SRC-2 and accordingly reduce 
expression of SRC-2 metabolic target genes, including G6Pase. 
 
4.3 Physiological relevance of SRC-2 target genes                              
To our knowledge, no previous studies have focused on the effect of metformin on 
the steroid receptor coactivator family. Interestingly, a paper published by Chopra et 
al. in 2011 reported that SRC-2 is phosphorylated by AMPK in vitro, and that 
incubation of HepG2 cells with the AMP-analogue AICAR increased the ability of 
SRC-2 to coactivate FXR [22]. Notably, the association of FXR/SRC-2 was only 
found to be relevant with regard to transactivation of the bile acid export pump 
(BSEP/ABCB11) promoter. These findings were tied to the observed defective bile 
acid synthesis observed in SRC-2 knock-out mice and provide an explanation for the 
increased energy expenditure of SRC-2 knock-out animals compared to wild type 
littermates. Others have reported that metformin-induced AMPK activation is 
associated with perturbed bile acid homeostasis due to inhibition of FXR [145]. 
Physiologically, it is plausible that the AMPK pathway would both inhibit cholesterol 
and bile acid synthesis due to the energy-demanding nature of these anabolic 
pathways. It is widely established that metformin transcriptionally inhibits SREBP-1 
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[93], and that hepatic SREBP-1 expression levels are also decreased in response to 
inhibition of HMGCR and depletion of oxysterols [146]. Bile acids and oxysterols are 
derivatives of cholesterol and represent the endogenous ligands for FXR activation, 
which is known to stimulate the expression of the nuclear receptor small heterodimer 
partner (SHP/NR0B2) [147]. SHP consists only of a ligand-binding domain and no 
DNA binding domain and acts as a negative regulator of several nuclear receptors, 
and a transcriptional repressor of the CYP7A1 gene, the rate-limiting enzyme in bile 
acid synthesis [148, 149]. Thus, SHP functions as a negative feedback mediator of 
bile acid synthesis. Interestingly, SHP has been identified as a transcriptional target 
gene of SRC-2 [131] although the implications of this remains unknown. 
Incidentally, it has also been shown that metformin upregulates SHP [150]. Further 
studies are required to solve the role of SRC-2 in the complex regulatory networks of 
cholesterol and bile acid synthesis. 
SRC-2 liver knock-out mice are phenotypically characterized by fasting 
hypoglycemia and glycogen immobilization due to reduced G6Pase expression [19]. 
In line with these results, we demonstrated in paper II that PKA-mediated 
proteasomal degradation of SRC-2 resulted in a complete loss of ability to coactivate 
RORα and transactivate the G6Pase promoter. We also observed that PGC-1α activity 
on the same promoter requires the presence of SRC-2. These findings point to SRC-2 
as a critical mediator of gluconeogenesis by promoting expression of G6Pase. 
Furthermore, since SRC-2 activity is abolished in response to potent stimulation of 
the cAMP/PKA pathway, our findings may explain the downregulation of hepatic 
gluconeogenesis during long-term starvation, which is prevailingly characterized by 
abundant glucagon signaling.  
We show in paper III that metformin transcriptionally represses SRC-2 and 
inhibits recruitment of SRC-2 to RORα at the proximal G6Pase promoter. This may 
partly explain the ability of metformin to inhibit gluconeogenesis at the 
transcriptional level. Our results are in line with the established importance of 
coactivators in the regulation of gluconeogenesis. The ability of metformin to activate 
the AMPK pathway and inhibit CRTC2/TORC2-mediated expression of PGC-1α is 
well established [74, 151]. Interestingly, it has been reported that metformin retains 
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its inhibitory effect on gluconeogenic gene expression in absence of both LKB1 and 
the AMPK enzyme [152]. The AMPK-independent effects of metformin are poorly 
characterized and the exact mechanisms by which this anti-diabetic drug works 
remain elusive. Rather than pursuing the effect of AICAR on SRC-2 function, we 
chose to focus on metformin instead due to its clinical relevance. Metformin 
hydrochloride was diluted in water and added to cell media to final concentrations in 
the millimolar range, which is a widely established dosage in terms of cell 
experiments. Metformin enters cells primarily via the organic cation transporter 1 
(OCT1) membrane channel, and it has been shown that genetic variation of the OCT1 
impact metformin uptake in vivo [153]. We confirmed expression of OCT1 in both 
FaO and HepG2 cell lines. 
 At the core of de novo lipogenesis is the rate-limiting enzyme fatty acid 
synthase (FASN/FAS), a multi-subunit enzyme that generates palmitate from 
sequential addition of two carbons to malonyl-CoA. As expected, hepatic FASN 
expression levels have been found to be increased in NAFLD [154]. A new paradigm 
to have emerged is the FASN-driven “lipogenic state” which points to FASN as a 
pathologic driver of insulin resistance, fat accretion and cancer [155]. Originally 
characterized as a LXR target gene, it is now known that hepatic FASN is regulated 
at the transcriptional level by also SREBP-1 and ChREBP [84]. In paper III, we 
demonstrated that SRC-2 acts as a coactivator of SREBP-1 on the FASN promoter. 
This finding is in line with the findings of a recent publication by Dasgupta et al., 
where it was shown that SRC-2 exerts ‘metabolic programming’ to promote 
lipogenesis and survival of prostate cancer cells [30]. It was also demonstrated that 
the presence of glutamine and mTORC1 activity was required to enable SRC-2 
coactivation of SREBP-1. Our cell experiments for paper III were performed with the 







5. Future perspectives 
 
A comprehensible analysis of hepatic SRC-2 target gene networks is required for to 
elucidate its multifaceted roles in regulating liver metabolism. For paper III, we 
planned to perform a ChIP-sequencing of SRC-2 to complement the microarray data 
in FaO cells treated with or without metformin. However, no tested antibodies were 
compatible with immunoprecipitation of the rat antigen SRC-2, and no data was 
retrieved. If pursued for future studies, this analysis should be performed in 
conjunction with microarray using hepatic tissue from wild type and SRC-2 knock-
out mice treated with or without metformin. Data from ChIP-sequencing may also 
elucidate novel nuclear receptors that are coactivated by SRC-2 on mutual target 
promoters. Identifying novel interaction partners of SRC-2 should be useful for 
elucidating mechanisms that may be relevant to human diseases including diabetes 
and metabolic complications associated with obesity. It would also be interesting to 
ascertain whether the metformin-reduced downregulation of SRC-2 is AMPK-
dependent and involves EGR1. Moreover, a possible connection between the known 
inhibitory effect of metformin on the mTORC1 pathway with regard to mTORC1-
dependent activation of SRC-2 should be explored. This was unfortunately outside 
the scope of paper III.  
 It would also be interesting to investigate whether SRC-2 in skeletal muscle 
and adipose tissue is relevant to the insulin sensitizing mechanisms by which 













In this thesis it was demonstrated that SRC-2 is subject to both transcriptional and 
post-translational regulation. Furthermore, the available amount of cellular SRC-2 
protein determines the rate of transcription of SRC-2 target genes. In the liver, SRC-2 
regulates gluconeogenesis and biosynthesis of lipids and cholesterol at the 
transcriptional level. 
 
The following conclusions can be drawn from this study: 
 
 Prolonged activity of the cAMP/PKA signaling pathway stimulates the 
targeted degradation of SRC-2 protein. CREB directly interacts with SRC-2, 
and is an integral factor in the PKA-mediated degradation of SRC-2. 
 
 The nuclear receptor RORα and its coactivator SRC-2 stimulate 
transactivation of the G6Pase promoter. In the absence of RORα/SRC-2, the 
ability of PGC-1α to transactivate the G6Pase promoter is diminished. By 
regulating the amount of SRC-2 protein available to coactivate RORα, 
prolonged cAMP/PKA signaling may attenuate the rate of G6Pase expression 
and gluconeogenesis during long-term starvation. 
 
 The anti-diabetic drug metformin dose-dependently represses transcription of 
both SRC-2 and its target genes. Metformin reduces recruitment of SRC-2 to 
RORα on the G6Pase promoter and markedly downregulates G6Pase 
expression. Metformin also inhibits transcription of several SRC-2 target 
genes involved in biosynthesis of lipids and cholesterol where SRC-2 acts as a 
coactivator of SREBP-1. 
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a b s t r a c t
Fasting hormones activate the cAMP/PKA signaling pathway and stimulate expression of hepatic glu-
coneogenic enzymes including glucose-6-phosphatase (G6Pase). Previously it was shown that steroid
receptor coactivator 2 (SRC-2) knock-out mice exhibit fasting hypoglycemia and that SRC-2 coactivates
RAR-related orphan receptor alpha (RORa) at the proximal G6Pase promoter. We have investigated the
upstream regulation and functional implications of this RORa/SRC-2 complex on G6Pase expression. In
HepG2 cells, overexpression of the catalytic PKA subunit (PKA-Ca) reduced the SRC-2 protein level,
recruitment to the G6Pase promoter, and its ability to coactivate RORa. Knock-down and transactivation
experiments employing G6Pase promoter constructs demonstrated that RORa and SRC-2 are required for
PGC-1a to stimulate G6Pase expression. These results suggest that PKA inhibits SRC-2 coactivation of
RORa and in turn reduces PGC-1a dependent regulation of G6Pase. This indirect feedback mechanism
may underlie the suppression of gluconeogenesis throughout long-term starvation.
© 2015 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
During short-term fasting the continued demand for circulating
glucose in mammals is supplied by mobilization of hepatic
glycogen into free glucose through the process of glycogenolysis
(Nordlie, 1974, 1979; van Schaftingen and Gerin, 2002). In this
phase, stable plasma glucose levels rely on a finite hepatic glycogen
storage that rapidly depletes. Following glycogen depletion and
overnight fasting, new glucose is generated by the process of
gluconeogenesis to avoid hypoglycemia (Unger et al., 1963; Cahill,
2006).
Common to both glycogenolysis and gluconeogenesis is the
rate-limiting enzymatic dephosphorylation of glucose-6-
phosphate into free glucose that can be secreted into plasma and
this reaction is catalyzed by the catalytic subunit of glucose-6-
phosphatase (G6Pase) (Nordlie, 1974, 1979; van Schaftingen and
Gerin, 2002; Nordlie et al., 1999; Chopra et al., 2008). This
enzyme is expressed mainly in the liver and kidneys where it is
translated into the membrane of endoplasmic reticulum (Nordlie,
1979; Arion et al., 1976). The rate-limiting enzymes phosphoenol-
pyruvate carboxykinase (PEPCK) and G6Pase control the output of
gluconeogenesis and are regulated at the transcriptional level by
key metabolic hormones including glucagon, glucocorticoids, and
insulin (Sever and Glass, 2013). A key downstream mediator of
glucagon signaling is peroxisome proliferator-activated receptor
gamma coactivator 1 alpha (PGC-1a), which regulates several
metabolic processes including gluconeogenesis and mitochondrial
biogenesis (Lin et al., 2005; Finck and Kelly, 2006; Schilling et al.,
Abbreviations: G6Pase, glucose-6-phosphatase; SRC, steroid receptor coac-
tivator; PKA, protein kinase A/cAMP-dependent protein kinase; RORa, retinoic acid
related orphan receptor alpha; RORE, RORa response element; PGC-1a, peroxisome
proliferator-activated receptor gamma coactivator 1-alpha; HNF4a, hepatocyte
nuclear factor 4-alpha.
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2008). Fasting is accompanied by an increase in glucagon levels and
activation of the cAMP/PKA-dependent pathway (Unger et al.,
1963). Specifically, PKA-mediated phosphorylation of cAMP
response element binding protein (CREB) at Ser133 facilitates the
interaction with its coactivator CRTC2/TORC2 and enables tran-
scription of PGC-1a (Lin et al., 2005; Finck and Kelly, 2006). PGC-1a
in turn promotes expression of G6Pase by coactivating hepatocyte
nuclear factor 4-alpha (HNF4a) (Sever and Glass, 2013). Conversely,
insulin signaling represses PGC-1a expression by stimulating
ubiquitin-mediated degradation of TORC2. In type 2 diabetes, the
combination of insulin resistance and elevated serum glucagon
exacerbates hepatic gluconeogenesis resulting in increased
endogenous glucose production and fasting hyperglycemia (Sloop
et al., 2005).
Steroid receptor coactivator 2 (SRC-2) is a member of the p160
steroid receptor coactivator family of three genetically distinct yet
structurally and functionally similar members (Stashi et al., 2014;
York and O'Malley, 2010). The SRCs associate with nuclear hor-
mone receptors (NRs) in a ligand-dependent manner to enhance
transcriptional activity (Stashi et al., 2014; Johnson and O'Malley,
2012). NRs respond to hormonal signaling by binding directly to
DNA and play important roles in a variety of physiological processes
including development, homeostasis, andmetabolism (Picard et al.,
2002; O'Malley, 2006). Phenotypic observations of global or liver-
specific SRC-2 knock-out mice include hypoglycemia in fasted
state and reduced expression of hepatic G6Pase in both fed and
fasted state (Chopra et al., 2008). Interestingly, loss-of-function
mutations of the G6Pase gene (glycogen storage disorder-1a)
exhibit a similar phenotype characterized by fasting hypoglyce-
mia due to immobilization and accumulation of hepatic glycogen
(Lei et al., 1996). It has been shown that SRC-2 regulates G6Pase
expression by coactivating the retinoic acid receptor-related
orphan receptor alpha (RORa) at an evolutionary conserved RORa
response element (RORE) sequence of the proximal G6Pase pro-
moter (54 to 49, relative to transcription start site (TSS) in
mouse) (Chopra et al., 2008). Indeed, SRC-2 mediated coactivation
of RORa greatly enhanced promoter activity and the rate of tran-
scription of G6Pase (Chopra et al., 2008). Located adjacent to a
HNF4a binding sequence (76 to63 relative toTSS inmouse), this
particular RORE sequence has previously been identified as a nu-
clear receptor half-site required for PGC-1a mediated G6Pase
expression (Schilling et al., 2008).
Continued fasting leads to progressively elevated levels of
glucagon that corresponds to increased levels of intracellular
cAMP (Unger et al., 1963). We have previously demonstrated that
SRC-2 is subject to regulation by the cAMP/PKA pathway in other
contexts (Hoang et al., 2004; Fenne et al., 2008). This study was
designed to investigate whether stimulation of the cAMP/PKA
signaling pathway regulates G6Pase expression via RORa and SRC-
2.
2. Materials and methods
2.1. Cell culture and transfection assays
The human hepatoma cell line HepG2 was purchased from ATTC
and cultured at 37 C and 5% CO2 in presence of water bath con-
taining fungizone (Bristol-Myers Squibb, New York City, NY, USA).
HepG2 cells were grown in EMEM (Lonza, Basel, Switzerland)
supplemented with 10% FBS (Gibco, Waltham, MA, USA), 1%
penicillin-streptomycin (Sigma, St. Louis, MO, USA) and 2 mM L-
glutamine (Lonza) and seeded in multi-well plates one day prior to
transfection. Plasmids were transfected using TransIT-LT1 reagent
(Mirus, Madison, WI, USA) according to the manufacturer's in-
structions. Mutant reporters were made using the QuickChange II
Site-Directed Mutagenesis Kit (Agilent, Santa Clara, CA, USA) ac-
cording to manufacturer's instructions or with less overlapping
primers as described (Liu and Naismith, 2008). All reporter con-
structs were verified by DNA sequencing. The following reporter
plasmids were used: the promoter sequence between 231/þ66
relative to transcriptional start site of the wild type (WT) mouse
pGL3-WT-mG6Pase-luc; pGL3-DRORE-mG6Pase-luc; and pGL3-
DHNF4a-mG6Pase-luc. The following expression plasmids were
used: pCMV-XL5-RORa; pCMV empty vector; pCR3.1-SRC2;
pCR3.1-empty vector; pcDNA4-6xHis-hRORa1-HisMax; pCMV5-
Ca; pCDNA-PGC-1a and pCDNA-empty vector. For indicated ex-
periments, cells were treated with DMSO (Sigma) as vehicle,
MG132 (Sigma), RORa ligand SR1001 (Sigma), forskolin (Sigma), a
combination of cAMP-elevating agents (10 mM forskolin and 50 mM
IBMX (Sigma) and 500 mM N6-monobutyryladenosine-30,50-cyclic
monophosphate (6 MB-cAMP) (Sigma), or transfected with the PKA
catalytic subunit vector pCMV5-Ca. For knock-down experiments
we employed TransIT-TKO transfection reagent (Mirus) per the
provided instructions. SRC-2 (Ncoa2), RORa (Rora) or non-targeting
(NT) SMARTpool ON-TARGETplus siRNA (Dharmacon, Lafayette, CO,
USA) was incubated with cells at a final concentration of 100 nM for
72 h.
2.2. RNA isolation, cDNA synthesis and mRNA quantification
Cells were lysed in 350 ml RLT buffer and RNA was isolated
using QIAcube and RNEasy mini kit (Qiagen, Hilden, Germany).
Sample RNA concentrations were measured by NanoDrop and
cDNA was synthesized from normalized amounts of total RNA
with Transcriptor First Strand kit (Roche, Basel, Switzerland) ac-
cording to the manufacturer's mixed primer protocol. The cDNA
was diluted 1:10 prior to mRNA quantification by real-time SYBR I
Green RT-qPCR of target genes relative to reference gene RPL4.
Primer sequences are presented in the supplemental information
Table 1. Relative mRNA quantification was calculated using the
deltaedelta Ct method.
2.3. Transactivation assays
Cells were transfected 48 h prior to lysis with buffer containing
25 mM Tris Acetate-EDTA (pH 7.8), 2 mM dithiotheitol, 1 mM EDTA,
10% glycerol and 1% Triton X-100. Sample lysate was analyzed with
luciferase kit (BioThema, Handen, Sweden) on a FLUOStar Optima
(BMG Labtech, Ortenberg, Germany) luminescence plate reader.
2.4. Protein quantification, SDS-PAGE and Western blot
Cells were harvested in buffer containing 50 mM TriseHCl (pH
7.5), 200 mM NaCl, 5 mM EDTA, 1% NP-40, 1ug/ml aprotinin, 5 mM
N-ethylmaleimide, 100 nM sodium orthovanate, 0.2 mM PMSF and
1 EDTA-free protease inhibitor cocktail (Roche). Sample protein
concentrations were measured using a detergent compatible pro-
tein assay (Bio-Rad, Hercules, CA, USA) in accordance with manu-
facturer's protocol. 4 loading buffer was added to samples of equal
protein amounts and boiled at 95 C for 5min. Samples were loaded
onto precast 4e20% gradient Mini-Protean TGX gels (Bio-Rad) and
run at 150 V for 1 h in a mini PROTEAN tetra Powerpac system (Bio-
Rad). Protein was subsequently transferred to nitrocellulose
membranes using iBlot system (Invitrogen, Waltham, MA, USA).
Membranes were blocked using 5% non-fat dry milk in PBS-T
overnight at 4 C, incubated with antibodies with 3% BSA in PBS-
T, developed using Femto substrate (Thermo Scientific, Waltham,
MA, USA) and analyzed using a ChemiDoc XRS camera (Bio-Rad)
and QuantityOne software. The following antibodies were
employed: anti-SRC-2 (BD Biosciences #610985); anti-beta-Actin
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(Abcam ab8227); anti-RORa (Sigma AV45607); HRP goat-anti
mouse IgG (BD Biosciences #554002) and HRP goat-anti rabbit
IgG (Thermo Scientific #31460).
2.5. Chromatin immunoprecipitation (ChIP)
HepG2 cells were seeded (2.0  106) in 92 mm plates per
treatment as indicated prior to fixation in 1% (v/v) formaldehyde for
10 min and quenching with glycerol. Cells were washed in ice-cold
PBS and further processed with the EZ-Magna ChIP kit (Millipore,
Billerica, MA, USA). Sonication was set to 8 min (30 s on/off cycles)
using a cold-water bath Bioruptor (Diagenode, Denville, NJ, USA).
The following antibodies were used in conjunction with protein A
magnetic beads in over-night immunoprecipitation: anti-RNA Pol II
(Millipore #05-623B); normal rabbit IgG (Millipore #PP64B); anti-
SRC-2 (Bethyl #300-346A) in quantities of 5 ml per sample. The
primers used to direct amplification of the proximal RORE on the
human promoter of Glucose-6-Phosphatase, catalytic (G6Pc) in
end-point SYBR I Green real-time qPCR were 50-
CGTGGTTTTTGAGTCCAAAGAT-30 (forward) and 50-CCCCTGTTTTA-
TATGCCCTGT-30 (reverse). Primer specificity was verified in silico
using the UCSC Genome Browser (http://genome-euro.ucsc.edu).
Sample qPCR data was normalized that of respective 1% input
samples for each treatment.
2.6. Electrophoretic mobility shift assay (EMSA)
The promoter sequence of Glucose-6-phosphatase, catalytic
(G6pc) (NCBI gene 14377, refseq NM_008061) was retrieved from
the TRED database (https://cb.utdallas.edu/cgi-bin/TRED/tred.cgi?
process¼home) and verified by the EPD database (http://epd.
vital-it.ch). Complementary single-stranded oligonucleotides sur-
rounding the putative proximal RORE were purchased from Sigma
and 2.8 nM of each forward and reverse oligonucleotide were
combined and precipitatedwith 1:10 volume of 3M sodium acetate
and 2 volumes of ice-cold 96% ethanol and left for minimum 1 h
at 80 C. Precipitates were centrifuged at 13000 g for 30 min at
4 C prior to supernatant removal and pellet resuspension in 100 mL
hybridization buffer (10 mM TriseHCl at pH 8.0, 1 mM EDTA,
50 mM NaCl). Solution was heated to 70 C for 10 min followed by
incubation at room temperature for 90 min. Annealed double-
stranded oligonucleotides were precipitated again as described
above and resuspended in 37 mL TE buffer (Qiagen). The following
oligonucleotides were used to create the mG6Pase-RORE probe:
50-GGGCTGGGTTGACCTACAGACTGAATCC-30 and 50-GGATTCAGT
CTGTAGGTCAACCCAGCCC-30, and the consensus RORE probe mutant
probe was made by combining: 5-GGGCTGGGTTGACCT
ACATACTGAATCC-30 and 50-GGATTCAGTATGTAGGTCAACCCAGCCC-30.
The core nuclear receptor half-site is underlined, RORa recognition
site-specific A/T rich region is shown in italics and mutation site is
emphasized in bold letters. 50 ng double-stranded probes were
labeled using T4 polynucleotide kinase (Promega, Madison, WI, USA)
and 25 mCi [g-32P]dATP (Nerliens Meszansky, Oslo, Norway) ac-
cording to manufacturers' instructions. Labeled probe was diluted
1:2 in 50 mM Tris/HCl, pH 7.5 to give a probe concentration of 1 ng/
mL and purified through 7K Zeba spin column (Thermo Scientific)
prior to scintillation count. Typical incorporation was 300.000 cpm/
ng probe. In vitro transcription and translation of pcDNA4-6xHis-
hRORa1-HisMax, pCMV-Ca and empty vector negative control were
made using cold methionine and the TNT Quick Coupled Tran-
scription system (Promega) according to instructions. Parallel TNT
expression assay using 35S-methionine was performed to protein
expression by SDS-PAGE and autoradiography. The following com-
ponents were added to the binding reaction in subsequent order:
H2O, binding buffer (modified from Sato et al. (Sato et al., 2004) final
concentrations: 10 mM TriseHCl pH 7.5, 50 mM KCl, 1 mM DTT,
1 mM EDTA, 5% glycerol, 5 mM MgCl2 and 12.5 ng/mL sonicated
salmon sperm DNA), 200 ng competitive unlabeled probe (where
indicated) and 2.5 mL TNT lysate. For the functional PKA assay, TNT
lysate expressing RORa or empty vector was incubated with re-
combinant, purified PKA-Ca (0.18 mg/mL) in presence of 10 mM ATP,
protease and phosphatase inhibitors (Roche) in a 1 NEB buffer
(50 mM TriseHCl pH 7.5, 10 mM MgCl, 0.1 mM EDTA, 2 mM DTT,
0.01% Igepal) at 30 C for 30 min. After 20 min of pre-incubation on
ice, 200 pg labeled probe was added and the binding reaction was
performed at room temperature for 30 min. DNA-protein complexes
were separated on 10% non-denaturing TBE polyacrylamide gels
(Biorad) using ice-cold TBE running buffer. Visualization was
performed by autoradiography.
2.7. Statistics and graphics
Two-tailed, unpaired Student's t-test was used to evaluate
significance of results. Where explicitly indicated, One-way
ANOVA with linear trend or Dunnett's multiple comparison
post-test was used for statistical calculations. Significance was
defined at p  0.05 (indicated *) or p  0.01 (indicated **) or
p  0.001 (indicated ***). Unless explicitly stated, all figures
contain data from one representative out of at least three inde-
pendent experiments. GraphPad Prism v5.0 (GraphPad Software
Inc, La Jolla, CA, USA) and Adobe Illustrator (Adobe Systems Inc,
San Jose, CA, USA) were used for statistical calculations and
graphical presentation of data.
3. Results
3.1. Transcriptional activity of RORa and SRC-2 is inhibited by the
overexpression of the PKA catalytic subunit
Fasting hormones stimulate expression of G6Pase by activating
the cAMP/PKA signaling pathway (Sever and Glass, 2013). We have
previously shown that activation of the cAMP/PKA signaling
pathway can change the SRC-2 coactivator function (Fenne et al.,
2013) and target promoter recruitment (Fenne et al., 2008) while
stimulating SRC-2 proteasomal degradation (Hoang et al., 2004).
Since SRC-2 has been shown to regulate G6Pase expression by
coactivating RORa (Chopra et al., 2008), we wanted to investigate
whether activation of the cAMP/PKA pathwaymay affect the RORa/
SRC-2 dependent transcriptional regulation of G6Pase. First we
investigated the cAMP/PKA effect on a reporter system containing
the proximal promoter sequence of G6Pase (231/þ66 relative to
transcription start site). In order to induce a moderate level of PKA
activation, simulating early stages of fasting, respectively, cells were
treated with forskolin (FSK) or a combination of FSK, IMBX and
6MB-cAMP. Overexpression of the catalytic PKA-Ca subunit was
performed to mimic potent PKA activity corresponding to long-
term starvation. Overexpression of RORa significantly stimulated
the G6Pase reporter activity and we observed a synergistic effect
when RORa was overexpressed together with SRC-2 (Fig. 1A).
Importantly, addition of forskolin or the combination of forskolin,
IBMX and 6MB-cAMP stimulated the basal level of reporter activity
in presence of empty vectors proportionally to that observed upon
overexpression of RORa, SRC-2 or both. This suggests that the
cAMP/PKA signaling pathway does not stimulate the expression of
G6Pase by enhancing activity of the RORa/SRC-2 transcriptional
complex. In contrast, overexpression of PKA-Ca significantly
reduced reporter activity and completely abolished the transcrip-
tional synergy in cells overexpressing both RORa and SRC-2
(Vehicle vs. PKA-Ca, p < 0.01). This suggests that a strong activa-
tion of the PKA signaling pathway inhibits transcriptional activity of
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the RORa/SRC-2 complex on the G6Pase promoter. To verify that the
unchanged mG6Pase reporter activity upon treatment of cells with
FSK/IMBX/6MB-cAMP corresponded to only a moderate level of
PKA activation, we titrated the amount of PKA-Ca plasmid in cells
overexpressing RORa and SRC-2 (Fig. 1B). We observed that small
amounts of PKA-Ca did not impede the ability of RORa/SRC-2 to
transactivate the mG6Pase promoter, whereas higher levels of PKA-
Ca exhibited an inhibitory effect as observed before. Importantly,
this observation suggests that the observed reduction of reporter
activity in the transition from a moderate PKA activation (FSK/
IMBX/6MB-cAMP) to a strong PKA activation (PKA-Ca over-
expression) in Fig. 1A was not due to activation of different path-
ways. In this cell system, overexpression of the catalytic PKA-Ca
subunit corresponds to a vastly stronger PKA activity than that of
endogenous PKA activated by FSK or the combination of FSK/IBMX/
6MB-cAMP.
Fig. 1. Effect of the cAMP/PKA pathway on RORa/SRC-2 and G6Pase expression. A. The ability of SRC-2 to coactivate RORa and transactivate the mG6Pase reporter (231/þ66) in
response to activation of the cAMP/PKA pathway was assayed by transfecting and treating HepG2 cells as indicated. Activation of the cAMP/PKA signaling pathway was accom-
plished by the addition of either 10 mM forskolin (FSK), or a combination of 10 mM forskolin, 50 mM IBMX and 500 mM 6 MB-cAMP (FSK/IBMX/cAMP), or overexpression of the PKA
catalytic subunit (PKA-Ca). Reporter activity of sample lysate is presented as mean arbitrary luciferase units ± SEM of biological triplicates. B. HepG2 cells were transfected with
mG6Pase-luc reporter, full-length RORa and SRC-2 plasmids in presence of an increasing amount of PKA-Ca. The maximal PKA-Ca plasmid amount of 1 corresponds to the default
level used in all other experiments. Data is represented as mean arbitrary luciferase units ± SEM of biological quadruplicates. C. Effect of cAMP/PKA pathway activation on
expression of indicated genes. HepG2 cells treated as indicated for 48 h and endogenous mRNA levels of G6Pase, RORa and G6Pase mRNA relative to reference gene RPL4 were
quantified by RT-qPCR. The average ± SEM of biological triplicates from a representative experiment is shown. D. Western blotting of annotated endogenous proteins with beta-
Actin (ACTB) loading control from lysate of HepG2 cells treated as indicated for 48 h. A representative result of three independent experiments is shown. E. Volumetric densitometry
analysis of SRC-2 protein amount relative to ACTB based on three independent experiments. F. HepG2 cells were transfected with PKA-Ca or an equivalent empty vector and
incubated in the absence or presence of 1 mM MG132 proteasome inhibitor for 48 h prior to analysis of lysate by Western blot. G. SRC-2 protein level was normalized to that of ACTB
in densitometry analyses of three independent experiments. H. Promoter activity of mG6Pase reporter in response to titration with increasing amounts (100 ng transfected DNA)
of SRC-2 plasmid in presence or absence of RORa. Data represent mean luciferase activity ± SEM of biological quadruplicates. 1-way analysis of variance with post test for linear
trend was applied to analyze promoter activity in response to increasing amounts of SRC-2 in the presence of RORa. In figures E and G, *p < 0.05 (Student's t-test).
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Next we subjected HepG2 cells to treatment with FSK, the
combination of FSK/IMBX/6MB-cAMP, or transfection with PKA-Ca
in order to determine mRNA levels of G6Pase, SRC-2 and RORa
(Fig.1C).We found that G6PasemRNAwas significantly upregulated
in response to moderate PKA activation. Supporting the findings
from the luciferase system, we observed that G6Pase mRNA level
was significantly reduced to baseline level when PKA-Ca was
overexpressed. In contrast, mRNA levels of RORa and SRC-2
remained unchanged regardless of PKA activity. This implies that
the ability of strong PKA activity to inhibit RORa/SRC-2 transcrip-
tional activity is not attributable to changes in mRNA expression
levels of RORa or SRC-2. Similar findings were observed in the rat
hepatoma FaO cell line (data not shown). Furthermore, using
HepG2 lysate from identical experiments we found that endoge-
nous protein levels of RORa relative to load control b-actin (ACTB)
were also insensitive to PKA activity (Fig. 1D). However, as previ-
ously reported (Hoang et al., 2004), a reduction of endogenous SRC-
2 protein level relative to ACTB was observed when PKA-Ca was
overexpressed. Densitometry analysis of Western blots from three
experiments confirmed that SRC-2 protein was significantly
reduced upon overexpression of PKA-Ca (Fig. 1E, p < 0.05). In order
to verify that PKA indeed caused SRC-2 degradation, HepG2 cells
were transfected with PKA-Ca or an equivalent amount of empty
vector in the presence or absence of the proteasome inhibitor
MG132 at a final concentration of 1 mM (Fig.1F). Again, we observed
that PKA-Ca significantly decreased the SRC-2 protein level.
Densitometry analyses confirmed that addition of MG132
decreased the basal turnover and, additionally, prevented PKA-Ca
mediated degradation of SRC-2 (Fig. 1G).
In light of the evident PKA-mediated degradation of SRC-2, we
wanted to investigate whether this mechanism is relevant for the
activity of the G6Pase promoter. Transfection assays in HepG2 cells
demonstrated that SRC-2 transactivated the G6Pase promoter in a
dose-dependent manner in the presence of RORa (Fig. 1H). As ex-
pected, SRC-2 was unable to stimulate promoter transactivation in
absence of RORa. These data indicate that G6Pase promoter activity
in part is determined by both the presence of RORa and the amount
of available SRC-2. Taken together, these results demonstrate that
that the ability of RORa/SRC-2 to transactivate the G6Pase promoter
is not enhanced by the PKA signaling pathway. In contrast, strong
PKA activity is accompanied by SRC-2 degradation, complete loss of
RORa/SRC-2 activity on the G6Pase promoter and reduction of the
G6Pase expression back to baseline level.
3.2. Recruitment of SRC-2 to the G6Pase promoter is determined by
PKA activity
Shilling et al. (Schilling et al., 2008) observed that the ability of
PGC-1a to promote transactivation of a G6Pase-luc reporter
plasmid was abolished upon introduction of a mutation in a
proximal RORa response element (RORE). The authors assumed
that this particular NR half-site represented a HNF4a binding site.
However, an enrichment of RORa at the proximal G6Pase promoter
was subsequently shown by Chopra et al. (Chopra et al., 2008),
demonstrated by chromatin immunoprecipitation (ChIP). The
consensus RORE sequence is a classical nuclear receptor half site
flanked by a 50 A/T-rich RORa-specific recognition sequence 50-(A/
G/T)(A/T)(A/T)(A/T)N(A/T)AGGTCA-30, where bold letters indicate
residues important for RORa binding (Giguere et al., 1994). We
aligned the mG6Pase-RORE reported by Chopra et al. with the
consensus RORE and found no similarity (data not shown). How-
ever, we hypothesized that RORa could bind to the reverse strand
and indeed, alignment of the reverse complement sequence re-
ported by Chopra with that of the consensus RORE resulted in a
near complete match. However, at the important position
underlined above, the mG6Pase-RORE contains a C (on the reverse
strand) as opposed to consensus and critical A or T. We therefore
expected that RORa binding would be weak, yet still functional as
indicated by our previous mG6Pase promoter activity assays. To
verify binding of RORa to mG6Pase-RORE, we performed EMSA
using a radiolabeled double-stranded probe containing the
mG6Pase-RORE sequence and in vitro transcribed and translated
V5-tagged RORa (Fig. 2A, left panel). A specific complex was indeed
formed when incubating mG6Pase-RORE probe with translated
RORa (lane 3), which was not observed with addition of increasing
molar excess unlabeled probe (lane 4e5) or when incubated with
unprogrammed reticolucyte lysate (lane 2). As a positive control,
we utilized the consensus RORE probe containing a C to A gain-of-
function mutation as explained above (Fig. 2A, right panel). As
expected, RORa bound to the positive control consensus RORE in a
strong and specific manner (lanes 9e11). To verify the specificity of
the RORa-RORE complex, we performed antibody-mediated
supershift-EMSA. When Anti-V5 antibody was added to the bind-
ing reaction, a supershift was clearly observed for the consensus
RORE (lane 12). This supershift was less pronounced for the
mG6Pase-RORE, and however, addition of the antibody was
accompanied by the disappearance of the lower band corre-
sponding to RORa bound probe (lane 6 vs lane 3). This may imply
that binding of the V5-antibody to RORa has somehow disrupted
interaction between RORa and the probe. This diminishing
disruption effect was also observed upon supershift of RORa with
respect to the consensus RORE probe compared to the corre-
sponding intensity of basal RORa binding to the same probe in the
absence of the V5-antibody (lane 12, vs lane 9). Given the already
weak binding of RORa to the mG6Pase-RORE, it is likely
that binding of the V5-antibody to the RORa fusion protein has
caused RORa to dissociate from the probe. Having confirmed the
ability of RORa to bind to the mG6Pase-RORE, we investigated
whether the affinity of RORa to the probes was altered in presence
of PKA-Ca in vitro (Fig. 2B). We observed that binding of RORa both
mG6Pase-RORE and consensus RORE was not significantly affected
by PKA.
We next assessed the recruitment pattern of RNA Polymerase II
(RNA Pol II) and SRC-2 to the G6Pase promoter in response to
stimulation of the cAMP/PKA pathway for 48 h in HepG2 cells,
using ChIP analysis (Fig. 3A). Recruitment of RNA Pol II to the
G6Pase promoter was in accordance with the observed G6Pase
mRNA levels presented in Fig. 1C for respective treatment condi-
tions. Notably, transfectionwith the PKA-Ca significantly decreased
enrichment of RNA Pol II at the G6Pase promoter to below that of
the baseline control. In presence of PKA-Ca we also observed a
significant reduction of SRC-2 protein at the proximal G6Pase
promoter, whereas addition of forskolin or a FSK/IBMX/6MB-cAMP
had no effect compared to basal recruitment. Taken together our
data suggest that strong PKA activity impedes recruitment of SRC-2
and subsequently RNA Pol II to the proximal G6Pase promoter. We
performed additional ChIP experiments in order to elucidate the
temporal recruitment of RNA Pol II and SRC-2 in response to
treatment of HepG2 cells with FSK/IMBX/6MB-cAMP for 45 min,
24 h and 48 h (Fig. 3B). The highest observed recruitment of RNA
Pol II and SRC-2 occurred at 45 min after stimulation of the cAMP/
PKA pathway, and significantly declined at 24 h and 48 h. This
suggests that prolonged PKA activity diminishes the presence of
SRC-2 and also RNA Pol II on the proximal G6Pase promoter.
3.3. Presence of SRC-2 is required for PGC-1a dependent
transactivation of the G6Pase promoter
Previous studies have demonstrated that the nuclear receptor/
coactivator complexes RORa/SRC-2 (Chopra et al., 2008) and
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HNF4a/PGC-1a (Schilling et al., 2008; Boustead et al., 2003) are
recruited to adjacent binding sites at the proximal G6Pase
promoter. Shilling et al. (Schilling et al., 2008) demonstrated that
the ability of PGC-1a to activate the G6Pase-luc reporter
was abolished upon introduction of a mutation in this relevant
RORE. Given the close proximity of these two NR-coactivator
complexes, we hypothesized that RORa/SRC-2 may be important
to facilitate transcriptional activity of HNF4a/PGC-1a at the
G6Pase promoter.
The compound SR1001 is an inverse agonist ligand for RORa that
has been shown to prevent interaction between RORa with its
coactivators and trigger recruitment of corepressors. SR1001 thus
effectively inhibits RORa-mediated transactivation, presumably
without altering its ability to bind DNA (Solt et al., 2011). We
therefore wanted to assess the implications of SR1001 on RORa-
dependent transcription of G6Pase.When HepG2 cells were treated
with increasing concentrations of SR1001, we observed a dose-
dependent downregulation of G6Pase mRNA (Fig. 4A), as also
observed byothers (Solt et al., 2011). This emphasizes the important
role of coactivation of RORa in the regulation of G6Pase expression.
Evenat themaximaldose,weobservednocytotoxic effect of SR1001.
Next we validated that SR1001 inhibited SRC-2 mediated coac-
tivation of RORa on the mG6Pase reporter (Fig. 4B). As expected,
SR1001 at a concentration of 100 mM completely abolished the
ability of SRC-2 to coactivate RORa. We also assessed whether the
absence of endogenous SRC-2 would also affect the ability of over-
expressed PGC-1a to transactivate the mG6Pase reporter (Fig. 4C).
Intriguingly, we observed that the effect of PGC-1awas dramatically
Fig. 2. Affinity of RORa to the mG6Pase-RORE and the consensus RORE is not altered by PKA. A. Binding of RORa to the mG6Pase-RORE probe shown in the left panel and consensus
RORE positive control probe shown in the right panel. Probes were incubated alone (lanes 1 and 7), with endogenous, unprogrammed TNT reticulocyte lysates (lanes 2 and 8) or
in vitro transcribed and translated V5-tagged RORa fusion protein (lanes 3e6 and 9e12). Progressive molar excess of unlabeled probes were added (lanes 4e5 and 10e11) to assess
specificity of RORa binding. Antibody-mediated EMSA supershift of V5-RORa in presence of the mG6Pase-RORE (lane 6) or consensus RORE (lane 12) probes was achieved by
addition of anti-V5 antibody. Apart from the upper supershift band, probes bound to RORa correspond to the lower visible band complexes on the gel, and NS denotes non-specific
bands. B. Binding of RORa to the mG6Pase-RORE (lanes 1e5) and consensus RORE (lanes 6e10) probes in the presence and absence of purified catalytic PKA-Ca subunit was assessed
by EMSA.
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reduced in the presence of 100 mM SR1001. These results indicate
that G6Pase is transcriptionally repressed upon displacement of
SRC-2 from RORa. Moreover, PGC-1a-dependent activation of the
G6Pase promoter is reduced in the absence of SRC-2.
In order to elucidate the functional relationship between RORa
and PGC-1a on the G6Pase promoter we introduced mutations in
either the RORa binding site (DRORE) or the HNF4a binding site
(DHNF4a) of the wild type (WT) proximal G6Pase 231/þ66 pro-
moter reporter. Luciferase assays in HepG2 cells demonstrated that
the capability of PGC-1a to transactivate both DRORE and DHNF4a
reporter constructs was abolished (Fig. 5A). As previously also
shown by Schilling et al., this indicates that the proximal RORE is
required for PGC-1a dependent activation of the reporter plasmid.
The observed synergistic effect of combining RORa and PGC-1a
led us to investigatewhether PGC-1a is a direct coactivator of RORa.
Accordingly we overexpressed both these factors in HepG2 cells
and measured promoter activity of the different mG6Pase variants.
RORa clearly stimulated transactivation of the WT construct, and
co-transfection with PGC-1a caused a synergistic increase in the
promoter activity, suggesting that PGC-1a could potentially coac-
tivate RORa directly (Fig. 5B). Introducing a mutation in the RORE
(DRORE) abolished the effect of RORa, and cotransfectionwith PGC-
1a produced only an additive effect, demonstrating the importance
of the RORE in facilitating PGC-1a mediated transcription.
Compared to the WT reporter, the ability of RORa alone to trans-
activate the DHNF4a reporter was not significantly impeded.
However, upon introduction of a mutation in the HNF4a binding
site, the contribution from PGC-1a in terms of reporter trans-
activation was statistically insignificant both in the presence and
absence of RORa. Taken together, these results suggest that PGC-1a
does not coactivate RORa directly, but rather that the presence of
RORa is required to facilitate the interaction between PGC-1a and
HNF4a on the proximal G6Pase promoter.
Next we used the wild type mG6Pase reporter constructs in
conjunction with either wild type (WT) or dominant negative (DN,
truncated and lacking DNA binding domain) RORa and simulta-
neous overexpression of empty vector or PGC-1a (Fig. 5C). As ex-
pected, the capability of DN RORa alone to activate the mG6Pase
promoter was comparable to baseline reporter activity, and six
times lower than that of WT RORa. Whereas WT RORa and PGC-1a
combined to strongly induce promoter activity, the combination of
DN RORa and PGC-1a exhibited near baseline level of trans-
activation. These results further demonstrate that presence of RORa
at the G6Pase proximal RORE is required to facilitate the function of
PGC-1a.
We previously demonstrated the ability of SRC-2 to coactivate
RORa on the G6Pase promoter and sought to further investigate
the effect of combining SRC-2 and PGC-1a in transactivation as-
says. In line with earlier observations, SRC-2 was convincingly
able to coactivate RORa in presence of an intact RORE. Combined
overexpression of SRC-2, PGC-1a and RORa resulted in an additive
effect on transactivation of the WT G6Pase reporter that was
severely diminished uponmutation of either the RORa (DRORE) or
HNF4a (DHNF4a) binding sites (Fig. 5D). This suggests that
presence of the RORa/SRC-2 facilitates the interaction between
PGC-1a and HNF4a.
In order to test the hypothesis that RORa/SRC-2 facilitates the
interaction between PGC-1a and HNF4a, we employed siRNA
against RORa and/or SRC-2 and measured transactivation of the
mG6Pase reporter with or without overexpression of PGC-1a
(Fig. 6A). We observed that knock-down of RORa or SRC-2 alone
and in combination dramatically decreased the effect of PGC-1a.
This result strongly suggests that PCG-1a requires the presence of
SRC-2 and RORa in order to stimulate G6Pase promoter activity.
Based on the results presented in the current article, we suggest the
following model for the cooperative transcriptional regulation of
G6Pase by RORa/SRC-2 and HNF4a/PGC-1a (Fig. 6B).
4. Discussion
The conversion of glucose-6-phosphate into free glucose is
catalyzed by G6Pase and marks the final and determining step in
Fig. 3. [1 column] PKA-Ca reduces recruitment of SRC-2 and RNA polymerase to
G6Pase promoter. A. Recruitment of endogenous RNA Pol II and SRC-2 to the genomic
G6Pase promoter in HepG2 cells after 48 h treatment with forskolin (FSK) or a com-
bination of 10 mM forskolin, 50 mM IBMX and 500 mM 6MB-cAMP (FSK/IBMX/cAMP), or
overexpression of the PKA catalytic subunit (pCMV-PKA-Ca). Immunoprecipitated DNA
was analyzed by qPCR using sequence specific primers to generate an amplicon
flanking the proximal RORE of the genomic human G6Pase promoter. Data was
normalized to respective 1% input samples and presented as mean fold recruitment
relative to RNA Pol II control treatment (DMSO and Empty vector) ± SEM of technical
triplicates. By convention, basal recruitment of RNA Pol II was defined as 1.0 and all
other data were normalized to scale accordingly. B. Recruitment of RNA Pol II and SRC-
2 at time points 45 min, 24 h and 48 h following treatment of HepG2 cells with 10 mM
FSK, 50 mM IBMX and 500 mM 6MB-cAMP (FSK/IBMX/cAMP). Data was normalized to
1% input and presented as arbitrary fold recruitment relative to RNA Pol II ± SEM of
technical triplicates. Negative control antibody (IgG) represents unspecific assay
background. Statistical annotations *p < 0.05 and **p < 0.01.
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both glycogenolysis and gluconeogenesis. These two processes are
physiologically related to fasting and alignwith the fact that G6Pase
is regulated at the transcriptional level by fasting hormone
signaling via the cAMP/PKA pathway. Previously, it has been shown
that SRC-2 coactivates RORa at the G6Pase promoter (Chopra et al.,
2008). In the current study, we demonstrate that RORa and its
coactivator SRC-2 are required for PGC-1a-mediated trans-
activation of the G6Pase promoter. By causing protein degradation
and reduced recruitment of SRC-2 to its target nuclear receptor
RORa at the G6Pase promoter, PKA indirectly impedes the ability of
the master gluconeogenic mediator PGC-1a to coactivate the
adjacently positioned HNF4a.
It is widely established that PGC-1a, a key mediator of gluco-
neogenic gene expression, is induced in response to activation of
the cAMP/PKA pathway. Treatment of cells with FSK or a combi-
nation of FSK/IBMX/6MB-cAMP induces moderate PKA activity and
increases G6Pase expression, but not via RORa/SRC-2. Interestingly,
overexpression of the PKA-Ca induced strong PKA activity and
significantly reduced the ability of RORa/SRC-2 to transactivate the
G6Pase promoter. These findings are partially attributable to the
finding that PKA reduces both the protein level and recruitment of
SRC-2 to RORa on the G6Pase proximal promoter. These results are
in line with previously published data demonstrating that pro-
longed stimulation of the cAMP/PKA signaling pathway reduces
SRC-2 coactivator activity (Fenne et al., 2013) and target promoter
recruitment (Fenne et al., 2008) while stimulating SRC-2 ubiq-
uitylation and proteasomal degradation (Hoang et al., 2013; Hoang
et al., 2004).
It has been shown by Schilling et al. that introduction of a mu-
tation shortly downstream of the HNF4a binding site at the prox-
imal G6Pase promoter significantly prevented PGC-1a-mediated
transactivation (Schilling et al., 2008). This site was later shown to
be a binding site for RORa (Chopra et al., 2008). Here, we show that
RORa binds this RORE located in the proximal G6Pase promoter and
adjacent to an HNF4a binding site. Notably, this RORE differs from
the consensus RORE in a single, but crucial residue in the RORa
specification site. We found that the binding affinity of RORa to the
mG6Pase-ROREwas weaker than that of the consensus RORE, albeit
still functional in both EMSA and transactivation assays. We also
demonstrate that the coregulator-modulating RORa ligand SR1001
alone is capable of dose-dependently reducing G6Pase mRNA by
displacing SRC-2 from RORa. This event in turn renders PGC-1a
unable to activate the G6Pase promoter. These findings illustrate
the importance of coactivators in the regulation of
gluconeogenesis.
It is well established that PGC-1a increases expression of several
metabolic enzymes including G6Pase in response to fasting and
following activation of the cAMP/PKA signaling pathway. Using
reporter constructs containing a mutation in either the RORa
(DRORE) or the HNF4a (DHNF4a) binding sites in the proximal wild
type (WT) promoter region of G6Pase, we demonstrate that the
proximal RORE is necessary for PGC-1a dependent transcription of
mG6Pase. Importantly, we observed that the ability of RORa to
transactivate the DHNF4a reporter was unimpeded compared to
Fig. 4. The RORa ligand SR1001 inhibits transcription of G6Pase by disrupting SRC-2 and
PGC-1a coactivation. A. Levels of HepG2 endogenous G6Pase mRNA in response to in-
cubation for 24 h with increasing concentrations of the RORa inverse agonist SR1001
were assessed by RT-qPCR. Amount of vehicle solvent (DMSO) was kept constant for all
treatments. Data represent mean G6Pase mRNA normalized to RPL4 ± SEM of biological
triplicates fromone of three independent experiments. One-way ANOVAwith Dunnett's
multiple comparisonpost testwas employed for statistical evaluation of this experiment.
B. Promoter activity of the mG6Pase-luc reporter in the absence or presence of 100 mM
SR1001was determined by luciferase. Cells were transfectedwith themG6Pase reporter
in combination with RORa and SRC-2 or C. RORa and PGC-1a as indicated, 48 h prior to
luminometric analysis of lysate. Data represent mean luciferase activity ± SEM of bio-
logical quadruplicates. **p < 0.01, ***p < 0.001, n.s., not significant.
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the WT reporter whereas there was no significant increase in
promoter activity upon addition of PGC-1a. This implies that PGC-
1a coactivates HNF4a and not RORa, and that presence of adjacent
RORa/SRC-2 is necessary for the full transcriptional effect of PGC-
1a. By overexpressing a dominant negative RORa variant unable to
bind DNA, we show that RORa is required for PGC-1a-mediated
transactivation of the mG6Pase promoter. Our additional experi-
ments employing the RORa ligand SR1001 or siRNA against RORa
and/or SRC-2 verified these findings.
Overexpression of PKA-Ca caused proteasomal degradation of
SRC-2 and reduced its recruitment to the G6Pase promoter,
whereas binding of RORa to the mG6Pase-RORE remained un-
changed. SRC-2 is subject to negative regulation by the cAMP/PKA
signaling pathway. Prolonged and sustained PKA activity pro-
motes ubiquitylation and proteasomal degradation of SRC-2
(Hoang et al., 2004; Fenne et al., 2008). By ChIP, we observed
that the presence of SRC-2 at the G6Pase promoter decreased
dramatically in response to both strong and prolonged PKA ac-
tivity. It is plausible that the concomitantly decreased recruitment
of RNA Pol II to the G6Pase promoter is a causal consequence of
the elimination of SRC-2. Fasting is characterized by a substantial
increase of circulating levels of hormones that stimulate the
cAMP/PKA signaling pathway (Unger et al., 1963). During long-
term fasting, hepatic gluconeogenesis is ultimately down-
regulated despite high amounts of circulating glucagon that sta-
bilize at the postabsorptive level which is also characterized by
minimal levels of insulin (Marliss et al., 1970). Accordingly, pro-
longed and pronounced PKA activity during long-term fasting
may cause degradation of SRC-2 and, in turn, prevent PGC-1a
dependent coactivation of HNF4a and thus cause downregulation
of G6Pase and gluconeogenesis.
In conclusion, we have found that RORa/SRC-2 dependent
transcriptional activation of G6Pase is inhibited in response to
strong PKA activity. This is the result of a targeted reduction in the
protein level and recruitment of SRC-2 to RORa at the proximal
G6Pase promoter. Moreover, the presence of RORa and SRC-2 at the
proximal promoter is required to facilitate the stimulatory effect of
PGC-1a on G6Pase expression.
Fig. 5. RORa and SRC-2 are required for PGC-1a dependent transactivation of the G6Pase promoter. Reporters labeled DRORE and DHNF4a annotate mutations in the proximal RORa
or HNF4a binding site, respectively, of the wild type (WT) mG6Pase promoter. The ability of PGC-1a to transactivate the indicated reporter constructs when overexpressed (A) alone
or (B) with RORa, (C) with dominant negative (DN) or wild type (WT) RORa or (D) in combination with RORa and SRC-2 was measured by luciferase assays. Data represent mean
luciferase activity units ± SEM of biological triplicates from one of three independent experiments.
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Fig. 6. Knock-down of RORa and/or SRC-2 reduces PGC-1a dependent transactivation
of G6Pase reporter. A. The effect siRNA-mediated knock-down of RORa and/or SRC-2 on
mG6Pase promoter transactivation. HepG2 cells were cotransfected with empty vector
(black bars) or PGC-1a (striped bars) and luciferase activity was measured 72 h after
transfection of siRNA at 100 nM final concentration. Data presents the mean arbitrary
luciferase activity units ± SEM of biological duplicates in one of three independent
experiments. B. We have demonstrated that the presence of nuclear receptor RORa and
its coactivator SRC-2 at the proximal G6Pase promoter RORa response element (RORE)
is required for effective transcription of G6Pase. Upon treatment of cells with the
inhibitory RORa ligand SR1001 or mutation of the RORE sequence we observed that the
master gluconeogenic regulator PGC-1a was unable to stimulate promoter trans-
activation via the adjacently positioned partner nuclear receptor HNF4a. Additionally,
we have demonstrated that presence of SRC-2 is required for optimal transactivational
effect of PGC-1a and that the cAMP-dependent protein kinase ultimately causes
degradation and reduced recruitment of SRC-2 to the G6Pase promoter. During fasting,
glucagon signaling via the cAMP/PKA pathway stimulates expression of PGC-1a and, in
turn, its gluconeogenic target genes including G6Pase. We propose that RORa-bound
SRC-2 facilitates the activity of PGC-1a at the G6Pase promoter and that PKA-mediated
degradation of SRC-2 may represent a mechanism by which hepatocytes transition out
of gluconeogenesis during long-term starvation.
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Metformin inhibits hepatocellular 
glucose, lipid and cholesterol 
biosynthetic pathways by 
transcriptionally suppressing 
Andre Madsen , , Olivera Bozickovic , , Jan-Inge Bjune , , Gunnar Mellgren , ,  & 
Jørn V. Sagen , ,
The ability of the anti-diabetic drug metformin to inhibit anabolic processes including 
gluconeogenesis and lipogenesis is partly attributable to activation of the AMP-activated protein 
treated cells revealed an overrepresentation of downregulated genes involved in biosynthesis of 
The p160 steroid receptor coactivator (SRC) family consists of the three distinct members SRC-1/
NCOA1, SRC-2/NCOA2/GRIP1/TIF2 and SRC-3/NCOA3/AIB1 that aid in the function of nuclear hor-
mone receptors and transcriptional regulation of target genes. The SRCs thus regulate metabolism and a 
variety of cellular processes by facilitating transcription of hormonally regulated target genes1–3. SRC-2 
regulates physiology and metabolism in a tissue-specific manner and is accordingly subject to regula-
tion by several cell signaling pathways and even circadian events4–7. Previous studies have demonstrated 
that SRC-2 contributes to obesity and insulin resistance8, fat accretion4,7, hepatic gluconeogenesis9,10 and 
biosynthesis of lipids4,9,10 and cholesterol6,9,10 at the transcriptional level. It has previously been shown 
that SRC-2 liver knock-out mice exhibit fasting hypoglycemia due to reduced hepatic expression of the 
rate-limiting gluconeogenic enzyme glucose-6-phosphatase (G6pc)10. This observation was coupled with 







the finding that SRC-2 acts as a coactivator of the orphan nuclear receptor RAR-related orphan receptor 
alpha (RORα ) on the proximal G6pc promoter10. Microarray profiling of liver from SRC-2 knock-out 
mice revealed reduced expression of Srebp1 and several key metabolic enzymes involved in gluconeo-
genesis (G6pc), lipogenesis (Fasn, Elovl6) and cholesterol synthesis (Hmgcr, Hmgcs1, Nsdhl, Cyp51)11. 
Notably, the sterol regulatory element binding protein 1 (SREBP-1) represents a master regulator of 
biosynthesis of lipids and cholesterol12. It was recently demonstrated that SRC-2 is activated in response 
to phosphorylation by the nutrient-sensor mammalian target of rapamycin complex 1 (mTORC1) and 
this event enables SRC-2 coactivation of SREBP-1 to promote lipogenesis and survival of particularly 
lipid-reliant prostate cancer cell models4.
Metformin, a synthetic biguanide drug, remains the preferred pharmacologic treatment for type 2 
diabetes13,14. The ability of metformin to suppress hepatic gluconeogenesis and other anabolic pathways 
including lipid and cholesterol biosynthesis is partly attributed to transient inhibition of the mitochon-
drial respiratory chain complex I and indirect activation of the energy-sensing AMP-activated protein 
kinase (AMPK) pathway15–17. Administration of metformin is associated with activation of AMPK and 
transcriptional repression of hepatic gluconeogenic enzymes18. Furthermore, AMPK inhibits lipogene-
sis by reducing activity of acetyl-CoA carboxylase14 and downregulating SREBP-1 and its target genes 
including fatty acid synthase (FASN)19. Several studies also support a role for metformin in the treat-
ment of non-alcoholic fatty liver disease (NAFLD)20–23. The pleiotropic AMPK pathway regulates cellular 
energy balance by modulating metabolism and this is partly achieved by inhibition of mTORC1 activ-
ity16,24. Interestingly, metformin-induced inhibition of both mTORC1 activity and gluconeogenic gene 
expression is retained in the absence of the catalytic AMPK subunits25,26. Thus, unlike the AMP analogue 
5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), the precise mechanisms by which metformin 
exerts its effects on hepatocyte metabolism remain elusive and several reports suggest that the central 
therapeutic properties of metformin in fact are mediated independently of the AMPK pathway25,27–29.
Liver knock-out SRC-2 mice are characterized by reduced expression of rate-limiting enzymes per-
taining to gluconeogenesis and biosynthesis of lipids and cholesterol4,6,9. This study aimed to determine 
whether the seemingly overlapping metabolic alterations induced by metformin may involve a down-
regulation of SRC-2.
Results
The established effects of metformin on hepatocellular 
metabolism led us to investigate whether metformin affects the expression of members of the steroid 
receptor coactivator family. The effects of increasing doses of metformin on relative expression levels of 
the steroid receptor coactivators SRC-1, SRC-2 and SRC-3 were assessed in the rat FaO hepatoma cell 
line (Fig. 1a). Whereas mRNA levels of SRC-1 and SRC-3 remained essentially unchanged in response 
to treatment with metformin, we observed a dose-dependent downregulation of SRC-2 mRNA. This 
range of metformin concentration (0–5 mM) was not cytotoxic to the cells and did not significantly affect 
mRNA levels of the house-keeping gene Rpl4. Expression levels of the gluconeogenic enzyme G6pc was 
included as positive control of the pharmacological effect of metformin. Since metformin significantly 
reduced SRC-2 mRNA we next investigated whether this downregulation also would affect endogenous 
SRC-2 protein level (Fig. 1b). As confirmed by densitometry of Western blots from three independent 
experiments, metformin concentrations at or above 1 mM caused a significant reduction of SRC-2 pro-
tein relative to beta-Actin (ACTB) in FaO cells. The above findings were replicated in HepG2 cells (data 
not shown). HepG2 cells were used for transactivation assays due to more effective plasmid transfection. 
Transactivation of a luciferase reporter construct under transcriptional control of the endogenous SRC-2 
promoter (containing bases − 1500 to + 1 relative to the SRC-2 transcription start site) was used to detect 
whether metformin downregulates SRC-2 at the transcriptional level. This reporter was dose-dependently 
inhibited by metformin relative to the control pGL-basic reporter (Fig. 1c). Taken together, these results 
demonstrate that treatment of cells with metformin decreases SRC-2 mRNA and protein levels.
cholesterol. In order to elucidate how metformin affects the hepatocellular transcriptome we per-
formed a significance analysis of microarray based on FaO cells treated with vehicle or 5 mM metformin 
and categorized the genes into respective biological processes using the PANTHER database (Fig.  2). 
As expected, mainly genes related to metabolic processes were differentially regulated by metformin 
and among the upregulated genes there was a significant overrepresentation of factors involved in fatty 
acid β -oxidation (p < 0.01). As for genes that were subject to transcriptional downregulation by met-
formin, there was a significant statistical overrepresentation of factors involved in lipid metabolic pro-
cesses (p < 0.05). Notably, several of the genes included in this category have previously been identified 
as transcriptional target genes of SRC-2 (Table  1). We next performed a separate qPCR validation of 
the microarray and overlapping SRC-2 target genes in which FaO hepatoma cells were incubated with 
increasing concentrations of metformin. Combining the annotated genes from Table 1 with other known 
SRC-2 target genes11, we observed that metformin dose-dependently downregulated mRNA levels of 
SRC-2 target genes involved in gluconeogenesis (G6pc), biosynthesis of lipids (Fasn, Elovl6) and choles-
terol (Hmgcr, Hmgcs1, Sqle, Nsdhl, Cyp51 and Egr1) (Fig. 3). In line withour microarray data, we found 
that the insulin receptor (Insr) was upregulated by metformin, and Igfbp, a known metformin-inducible 
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gene30,31, was included as a positive control. In order to verify that these genes indeed represent SRC-2 
target genes we performed transient siRNA knock-down of SRC-2 in FaO cells. Endogenous gene expres-
sion levels of all genes were measured by RT-qPCR 72 hours after siRNA transfection (Fig.  4a). We 
observed that knock-down of SRC-2 reduced G6pc expression and also significantly lowered mRNA 
levels of the included genes relating to lipid and cholesterol biosynthesis, with the only exception of Egr1. 
In the microarray, the Srebp1 gene was omitted due to the unsatisfactory FDR associated with this gene. 
Notably, Srebp1 but not Srebp2 has been previously identified as a SRC-2 target gene11 and we were only 
able to detect a moderate decrease of Srebp1 mRNA in response to knock-down of SRC-2. To validate 
that the observed changes in gene expression were indeed caused by the absence of SRC-2 protein we 
performed Western blot experiments to verify that the knock-down procedure had markedly reduced the 
SRC-2 protein level (Fig. 4b). Taken together, these results indicate that metformin causes transcriptional 
repression of key metabolic genes, of which several represent SRC-2 target genes.
Gene expression is 
preceded by binding of transcriptional activators and associated coactivators that ultimately recruit RNA 
polymerase II (RNAP) to target gene promoters. Bioinformatic analyses using Genomatix, UCSC and 



































































































Figure 1. Metformin inhibits expression of SRC-2. (a) The effect of vehicle (Veh, water) or metformin 
treatment on the endogenous mRNA expression levels of steroid receptor coactivators SRC-1, SRC-2 and 
SRC-3 in FaO hepatoma cells was determined by RT-qPCR. Metformin is known to downregulate G6pc 
expression and this gene was included as a positive control. Target gene expression was normalized to 
reference gene Rpl4 and represented as mean fold change relative to vehicle treatment ± SEM of biological 
triplicates. (b) FaO cells were treated as indicated and biological duplicates of 30 μ g lysate were analyzed 
by Western blotting using antibodies against SRC-2 and ACTB load control. Volumetric densitometry 
band analysis of SRC-2 protein was normalized to ACTB. Data present mean relative SRC-2 protein 
amount ± SEM of biological duplicates in three independent experiments. (c) HepG2 cells were transfected 
with luciferase reporter constructs under transcriptional control of the bases − 1500/+ 1 of the human 
SRC-2 promoter (pGL-SRC-2) or no promoter (pGL-empty). Reporter transactivation was measured 
by luminescence and is presented as the mean ratio between the two constructs, relative to vehicle 
treatment ± SEM of biological triplicates. *p < 0.05; **p < 0.01.
www.nature.com/scientificreports/
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binding motif at the proximal promoters of the above SRC-2 target genes, including Srebp1 itself, but 
with the exception of G6pc. On the proximal G6pc promoter, however, it has previously been shown 
that SRC-2 is a coactivator of the nuclear receptor RORα 10. In order to determine whether metformin 
reduces recruitment of SRC-2 to target gene promoters we performed chromatin immunoprecipita-
tion (ChIP) with respect to SRC-2 and RNAP protein and designed qPCR primers to amplify regions 
of proximal SREs of respective target gene promoters. For the G6pc promoter, primers were designed 
to amplify the relevant proximal RORα response element (RORE). Due to the inability of any tested 
Figure 2. Metformin-induced changes in the transcriptome. Based on the significance analysis of 
microarrays, genes that were differentially regulated by metformin were ordered into PANTHER biological 
categories. Only genes exhibiting a fold change (FC) equal to or greater than 1.5 (FC ≥ 1.5; upregulated) or 
equal to or less than − 1.5 (FC ≤ − 1.5; downregulated) and FDR ≤ 0.2 were included. Red and blue cells 
annotate significant overrepresentation of upregulated and downregulated gene categories, respectively.
Gene Description FC Biosynthetic pathway
Elovl6* Elongation of very long chain fatty acids protein 6 − 4.9 Lipid biosynthesis
Fasn* Fatty acid synthase − 2.4 Lipid biosynthesis
Hmgcr* 3-hydroxy-3-methylglutaryl-CoA reductase − 1.7 Cholesterol biosynthesis
Sqle* Squalene monooxygenase − 2.8 Cholesterol biosynthesis
Pigm Phosphatidylinositol glycan anchor biosynthesis class M − 4.6 Glycosylphosphatidyl-inositol biosynthesis
Hsd11b2 Corticosteroid 11-beta-dehydrogenase isozyme 2 − 2.7 Cortisol metabolism
Star Steroidogenic acute regulatory protein − 4.6 Steroid hormone biosynthesis
Gpd1 Glycerol-3-phosphate dehydrogenase − 2.1 Glycerol metabolism
Srd5a1 3-oxo-5-alpha-steroid 4-dehydrogenase 1 − 2.4 Steroid hormone biosynthesis
Fabp2 Fatty acid-binding protein − 4.5 Fatty acid transport
Table 1.  Transcriptional downregulation of lipid metabolic process genes by metformin. Gene entry 
comprising the statistically overrepresented microarray category “lipid metabolic process” (p < 0.05). Genes 
marked with *asterisks indicate previously established SRC-2 target genes11. Downregulation of the indicated 
genes in FaO hepatoma cells after treatment with metformin is annotated by the negative fold change (FC).
www.nature.com/scientificreports/
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ChIP-grade antibody to immunoprecipitate the rat SRC-2 antigen, HepG2 cells were used for this assay. 
HepG2 cells were incubated with vehicle (water) or metformin (5 mM) for 24 hours and ChIP end-point 
qPCR demonstrated that recruitment of both RNAP and SRC-2 to target gene promoters (G6PC, FASN, 
ELOVL6, HMGCR, HMGCS1, CYP51, NSDHL, SQLE and SREBP1) was significantly reduced upon treat-
ment with metformin (Fig.  5). These results are in agreement with the above findings, that both met-
formin and transient knock-down of SRC-2 reduce expression of the corresponding genes. Notably, the 
levels of unspecific recruitment observed with negative control IgG antibody appeared at very late qPCR 
cycles for all promoters. Thus, the insignificantly small background noise did not influence interpretation 
of results in terms of absolute quantification or by normalization according to the [Ct (Sample)] – [Ct 
(IgG)] subtraction method.
In light of the recent discovery that SRC-2 
acts as a coactivator of SREBP-1 in prostate cancer cells32 we wanted to examine whether this also 
occurred in a hepatocellular system. Additionally, we investigated whether SRC-2 could coactivate the 
related SREBP-2. A luciferase reporter construct under transcriptional control of the proximal FASN pro-
moter, containing bases − 220/+ 25 relative to transcription start site, was overexpressed in conjunction 
with full-length SREBPs and SRC-2 in HepG2 cells. The combined overexpression of SREBP-1 and SRC-2 
synergistically stimulated reporter transactivation, suggesting that SRC-2 indeed coactivates SREBP-1 
at the FASN promoter (Fig. 6a). In contrast, this effect was not observed with overexpression of SRC-2 
and SREBP-2, suggesting that SRC-2 does not act as a coactivator for SREBP-2 in this context (Fig. 6b). 
It is plausible that SRC-2 coactivation of SREBP-1 is also relevant with respect to other SREBP-1 target 
gene promoters.




























Figure 3. Downregulation of SRC-2 and its target genes by metformin. FaO cells were treated for 
24 hours with increasing concentrations of metformin prior to RT-qPCR analysis of endogenous mRNA 
expression levels of the indicated genes. Expression levels of Insr and Igfbp1 were included as positive 
controls of metformin-upregulated genes. Gene expression was normalized to the reference gene Rpl4 
and presented as mean fold change relative to vehicle treatment ± SEM of biological triplicates. One 
representative out of three independent experiments is shown. Where indicated, **p < 0.01.
www.nature.com/scientificreports/
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whether the absence of SREBP-1 and its coactivator SRC-2 would affect actual lipogenesis and cellular 
lipid content. Therefore we knocked down Srebp1 and SRC-2 in FaO hepatoma cells and starved the cells 
in serum-free medium for 48 hours prior to re-introduction of supplemented medium for 24 additional 
hours to facilitate lipogenic fat accretion. End-point Oil Red O staining demonstrated that cellular lipid 
content was reduced when Srebp1 and SRC-2 were knocked down simultaneously (Fig. 7a). Optical den-
sity quantitative measurements of the total cellular Oil Red O content confirmed that lipid levels were 
significantly reduced when both Srebp1 and SRC-2 were knocked down (Fig. 7b). We also starved FaO 
cells in serum-free medium for 48 hours prior to reintroduction of supplemented medium containing 
vehicle (water) or 5 mM metformin for 24 additional hours. Subsequent Oil Red O staining (Fig.  7c) 
and optical density quantification (Fig.  7d) demonstrated that cellular lipid contents were significantly 
reduced upon treatment with metformin compared to the vehicle control. These results demonstrate 
that Srebp1 and SRC-2 contribute to stimulate hepatocellular lipogenesis, whereas metformin has an 
inhibitory effect on this same process.
Discussion
Previous studies have demonstrated that hepatic SRC-2 transcriptionally promotes energy-demanding 
pathways including gluconeogenesis and biosynthesis of fatty acids and cholesterol. Here, we demon-
strate that the pharmacological effects of metformin extend to inhibit expression of SRC-2 and, in turn, 
SRC-2 target genes including rate-limiting enzymes pertaining to gluconeogenesis (G6pc) and biosyn-
thesis of lipids (Fasn) and cholesterol (Hmgcr and Hmgcs1). Previously it was shown that SRC-2 can act 

































































































Figure 4. Knock-down of SRC-2 reduces target gene expression. (a) Quantification of endogenous mRNA 
levels of SRC-2 and its target genes in FaO cells were measured by RT-qPCR, 72 hours after transfection 
with non-targeting (white bars) or SRC-2 (black bars) siRNA. Gene expression was normalized to reference 
gene Rpl4 and presented as mean fold change relative to transfection with NT siRNA ± SEM of biological 
triplicates of a representative experiment. (b) Protein levels of SRC-2 and load control ACTB were assessed 
by Western blot 72 hours after transfection of FaO cells with SRC-2 or NT siRNA. Quantification of protein 
bands was determined by densitometry. Data is presented as the relative SRC-2 protein amount ± SEM of 




the AMPK pathway are known to inhibit activity of both mTORC1 and SREBP-116,19. However, several 
pharmacological properties of metformin appear to be mediated independently of the AMPK pathway. 
Interestingly, the ability of metformin to inhibit both gluconeogenic gene expression and mTORC1 activ-
ity is retained in absence of the AMPK enzyme25,26.
Our initial findings show that metformin, in a concentration-dependent manner, causes transcrip-
tional downregulation and thus reduction of the available protein level of SRC-2, and this effect was 
not observed with SRC-1 or SRC-3. Microarray analysis of FaO hepatoma cells treated with or with-
out metformin revealed significant upregulation of genes involved in fatty acid β -oxidation. Conversely, 
there was a significant overrepresentation of downregulated genes associated with lipid biosynthesis, of 
which several were identified as SRC-2 target genes. Combining the latter entry with other metabolically 
relevant and previously established SRC-2 hepatic target genes identified by Jeong et al.11, we show that 
metformin in a dose-dependent manner inhibits transcription of this entire panel of SRC-2 target genes. 
The observed difference in dose responses for these genes is likely due to metformin differentially mod-
ulating the intrinsic activity of a large array of other transcription factors and coregulators on the various 
promoters. In line with the microarray results and the insulin-sensitizing property of metformin, we also 
show that metformin stimulates expression of the insulin receptor (Insr). Furthermore, the stimulating 
effect of metformin on expression of the insulin-like growth factor binding protein 1 (Igfbp1) has been 
described previously30,31. We also demonstrate that transient siRNA knock-down of SRC-2 is sufficient 
to significantly reduce mRNA expression of indicated SRC-2 target genes, with the exception of Early 
growth response 1 (Egr1). Notably, Egr1 has been reported to be a transcriptional target of SRC-211,33 
and is implicated in promotion of obesity and insulin resistance34, progression of prostate cancer35 and 
transcriptional regulation of lipid and cholesterol biosynthetic genes36. Interestingly, Egr1 was mark-
edly downregulated when cells were treated with metformin, and this could potentially be related with 
Vehicle (H2O) Metformin (5 mM)
Figure 5. Recruitment of SRC-2 and RNA polymerase to target gene promoters. Chromatin 
immunoprecipitation of RNA polymerase II (RNAP) and SRC-2 in HepG2 cells treated with vehicle (white 
bars) or 5 mM metformin (black bars). IgG represents assay background noise. Eluted sample DNA was 
subjected to qPCR amplification of regions overlapping known SREBP-1 binding sites at the proximal 
promoters of indicated target genes. For G6Pc, primers were designed to amplify the genomic promoter 
region flanking the proximal RORE. Signal quantification was normalized to that of respective treatment 1% 
input samples and data is presented as mean recruitment (% of input) ± SEM of biological triplicates in one 
representative out of three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001.
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the recent discovery that metformin administration after prostate cancer diagnosis is associated with 
decreased mortality37.
It has previously been shown that SRC-2 coactivates SREBP-1 and we therefore wanted to investigate 
whether the reduced SRC-2 expression and protein level in response to metformin treatment also would 
affect recruitment of SRC-2 to mutual target gene promoters. Sequential recruitment of the general tran-
scription machinery and ultimately RNA polymerase II is a core property of steroid receptor coactivators, 
including SRC-26. Using ChIP analysis we demonstrate that metformin significantly reduces recruitment 
of both endogenous SRC-2 and RNA polymerase II to sterol regulatory elements (SREs) located proxi-
mally at promoters of the entire panel of SRC-2 target genes. Notably, there is no SRE at the human G6Pc 
promoter. However, SRC-2 is a known coactivator of the nuclear receptor RORα on the G6Pc promoter10 
and we observed that recruitment of SRC-2 to the relevant proximal RORα response element (RORE) 
a.
b.
Figure 6. SRC-2 is a coactivator of SREBP-1. Transactivation of a luciferase reporter construct under 
transcriptional control of the endogenous − 220/+ 25 FASN promoter in response to combinatorial 
overexpression of SRC-2 and (a) SREBP-1 or (b) SREBP-2. Data are presented as mean arbitrary luciferase 
units ± SEM of biological quadruplicates. The presence or absence of coactivation synergy is illustrated. 
***p ≤ 0.001; n.s not significant.
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was significantly reduced when cells were treated with metformin. It is well established that transcrip-
tional control of coactivators is essential to the regulation of hepatic gluconeogenesis38. For example, 
the inhibitory effect of metformin and AMPK on the CREB regulated transcription factor 2 (CRTC2/
TORC2) impedes expression of the master gluconeogenic coactivator PGC-1α 39. Our observation that 
metformin inhibits SRC-2 expression is thus reconcilable with the established effect of metformin.
Previous studies have shown that transcription of SREBP-1 is positively regulated by insulin, and 
that metformin inhibits expression of SREBP-1 in vivo40. By downregulating both SREBP-1 expression 
and activity, metformin effectively inhibits lipogenesis and accumulation of hepatic lipids20,40,41. Here, 
we show in a hepatocellular system that SRC-2 is able to coactivate SREBP-1, but not SREBP-2, and 
that also SRC-2 is subject to transcriptional suppression by metformin. Our findings complement the 
established inhibitory effect of metformin on SREBP-1 and provide a new layer of complexity as to how 
metformin suppresses the transcriptional activity of SREBP-1 and lipogenesis. In particular, a key feature 
of SREBP-1 is to mediate expression of FASN which is the rate-limiting enzyme in de novo lipogenesis. 
Whereas knock-down of Srebp1 alone in our system was insufficient to functionally lower hepatocellular 
fat accretion, we observed a marked decline in intracellular fat content upon simultaneous knock-down 
of Srebp1 and SRC-2. This implies that SRC-2 markedly contributes to hepatocellular lipogenesis by 
coactivating SREBP-1. Metformin alone significantly reduced hepatocellular lipogenic fat accumulation, 
and this may partly be due to transcriptional suppression of SRC-2.
In conclusion, we provide evidence that treatment of cells with metformin is accompanied by 
reduced expression of SRC-2, which in turn impedes transcription of gluconeogenic G6Pc and coac-
tivation of SREBP-1 at key metabolic target gene promoters. We propose that the ability of metformin 
Figure 7. Inhibition of hepatocellular fat accretion. (a) Oil Red O staining of FaO hepatoma cells at 40x 
magnification after combinatorial knock-down with non-targeting (NT), SRC-2 and Srebp1 siRNA. Cells 
were starved in serum-free medium for 48 hours prior to introduction of medium supplemented with 10% 
FBS and 2 mM glutamine for 24 additional hours. Scale bar: 25 μ m. (b) Oil Red O staining of FaO cells at 
40x magnification following starvation for 48 hours prior to introduction of medium supplemented with 10% 
FBS, 2 mM glutamine and vehicle (Veh, water) or increasing doses of metformin for 24 additional hours. 
Scale bar: 25 μ m. (c) Quantitative analysis of Oil Red O content of cells from experiment (a) was done by 
measuring optical density of eluate at 490 nm. By convention, total Oil Red O content from cells transfected 
with NT siRNA was defined as 100% and all other samples were normalized accordingly. (d) Quantitative 
analysis of Oil Red O content of cells from the experiment (b). Data are presented as percent mean 
absorbance relative to cells treated with vehicle ± SEM of biological triplicates from one representative out of 
three or more independent experiments. *p < 0.05; **p < 0.01.
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to transcriptionally suppress gluconeogenesis and biosynthesis of lipids and cholesterol is in part due to 
transcriptional inhibition of SRC-2.
Methods
Cell culture, transfection and siRNA. Human HepG2 and rat FaO hepatoma cells were purchased 
from ATCC and cultured in a 5% CO2 incubator at 37 °C. The culture media EMEM (Lonza, Basel, 
Switzerland) and F-12 HAM (Gibco, Waltham, MA, USA) were supplemented with 10% fetal bovine 
serum (FBS) (Gibco), 1% penicillin-streptomycin (Sigma, St. Louis, MO, USA) and 2 mM L-glutamine 
(Lonza). Cells were seeded 24 hours prior to transfection to a standardized density of 50.000 cells/24-
well. For indicated experiments, cells were treated for 24 hours with metformin hydrochloride (Sigma) 
dissolved in sterile-filtered water. Transient plasmid transfections were performed in HepG2 cells using 
TransIT-LT1 reagent (Mirus, Madison, WI, USA) according to the manufacturer’s protocol. All plasmids 
were verified by sequencing. The following reporter constructs were used: pGL-basic; pGL-SRC-2 (con-
taining promoter bases − 1500/+ 1) and pFASN-luc (containing promoter bases − 220/+ 25). The fol-
lowing expression vectors were used: pSG5-HA-SRC-2; pSG5-empty; pcDNA3.1-2xFLAG-SREBP-1a and 
pcDNA3.1-2xFLAG-SREBP-2. For knock-down experiments we employed the TransIT-TKO transfection 
reagent (Mirus) with rat SRC-2 (Nuclear receptor coactivator 2) and rat non-targeting (NT) SMARTpool 
ON-TARGETplus siRNA (Dharmacon, Lafayette, CO, USA) at 100 nM final concentration. Cells were 
transfected with siRNA 72 hours prior to further analyses.
Transactivation assays. Cells were lysed with buffer containing 25 mM Tris Acetate-EDTA (pH 7.8), 
2 mM dithiotheitol, 1 mM EDTA, 10% glycerol and 1% Triton X-100 and sample lysate luciferase activ-
ity was analyzed using a luciferase kit (BioThema, Handen, Sweden) and a FLUOStar Optima (BMG 
Labtech, Ortenberg, Germany) luminescence plate reader.
Cells were lysed in RLT buffer (Qiagen, Hilden, Germarny) 
and processed for RNEasy (Qiagen) RNA isolation according to manufacturer’s protocol. Yield con-
centrations were measured by NanoDrop and 500 ng sample RNA was used for cDNA synthesis using 
High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Waltham, MA, USA) according 
to the manufacturer’s instructions. Synthesized cDNA was diluted 1:10 in water prior to SYBR I Green 
(Roche, Basel, Switzerland) real-time RT-qPCR of target genes relative to reference gene Rpl4. Primer 
sequences are presented in the Supplementary Table S1. Relative target/Rpl4 mRNA quantification was 
calculated using the delta-delta Ct method.
Microarray. FaO cells were treated with metformin (5 mM) or vehicle (water) for 24 hours prior to 
RNEasy (Qiagen) RNA purification. Integrity of total RNA (RIN value ≥ 9.0) from n = 3 biological rep-
licates per treatment was verified by Agilent Bioanalyzer prior to sample randomization and microarray 
(Agilent, Santa Clara, CA, USA) at the Genomics Core Facility, University of Bergen. No sample batch 
effects were observed. Significance analysis of microarrays was performed with J-Express software (http://
jexpress.bioinfo.no/site). Only genes exhibiting a fold-change FC ≤ − 1.5 or FC ≥ 1.5 relative to vehicle 
and false discovery rate (FDR) ≤ 0.2 were included in subsequent analyses. Functional annotations of 
valid genes and statistical overrepresentation of biological categories were retrieved in accordance with 
instructions42 using the PANTHER online database (pantherdb.org). The PANTHER library of 22957 
annotated genes (Rattus norvegicus) was used as reference list for calculating statistical overrepresenta-
tion. Microarray data is included as Supplementary Dataset.
Western blotting. Sample cell lysate (30 μ g) was loaded onto precast 4–20% Mini-Protean TGX 
gels (Bio-Rad, Hercules, CA, USA) and subjected to SDS-PAGE prior to iBlot (Invitrogen, Waltham, 
MA, USA) transfer to nitrocellulose membrane. The following antibodies were used: beta-Actin/ACTB 
(Abcam, Cambridge, UK, cat.no ab8227); SRC-2 (BD Biosciences, San Jose, CA, USA, cat. no 610985); 
HA-HRP (Roche, cat. no 12013819001); HRP goat-anti mouse IgG (BD Biosciences, cat. no 554002); 
HRP goat-anti rabbit IgG (Thermo Scientific, Waltham, MA, USA, cat. no 31460). Immunoblotted mem-
branes were developed using Femto substrate (Thermo Scientific) and analyzed on a ChemiDoc XRS 
imager (Bio-Rad) equipped with QuantityOne densitometry software. For densitometry analyses, volu-
metric protein band intensity was normalized to that of ACTB in the same gel lane.
Seeding of 2.0 × 106 HepG2 cells per 92 mm plate was 
performed one day prior to treatment with either 5 mM metformin or vehicle (water) for 24 hours. Cells 
were fixated with 1% (v/v) formaldehyde for 10 minutes and further processed using EZ-Magna ChIP 
kit (Millipore, Billerica, MA, USA) in accordance with the manufacturer’s protocol. Sonication was opti-
mized to 8 minutes (30 second on/off cycles) using a cold-water bath Bioruptor (Diagenode, Denville, NJ, 
USA). The following antibodies were used in conjunction with Protein A magnetic beads for over-night 
immunoprecipitation: ChIP-grade anti-RNA Pol II (Millipore #05-623B); normal IgG (Millipore #PP64B); 
ChIP grade anti-SRC-2 (Abcam ab9261) in quantities of 5 μ l per sample. Primers for end-point SYBR 
Green qPCR of eluted sample DNA were designed to amplify regions flanking proximal sterol regulatory 
elements (SREs) at target gene promoters. Primer specificities and SRE motifs were verified in silico using 
www.nature.com/scientificreports/
1 1SCIENTIFIC REPORTS
the UCSC Genome Browser (http://genome-euro.ucsc.edu) and Genomatix software. Primer sequences 
are listed in Supplementary Table S2. Quantification of samples by qPCR was normalized to parallel 
qPCR of 1% sonicated lysate input of respective treatments.
Oil Red O lipid staining. Cells were treated as indicated prior to fixation in 4% formaldehyde in PBS 
for 5 minutes followed by 1.5 hours with fresh 4% formaldehyde in PBS. Cells were washed twice with 
sterile water prior to incubation for 5 minutes with 60% isopropanol and being completely dried. Per 
well (12-well format) 1 ml of Oil Red O working solution (0.30 g Oil Red O in 100 ml 99% isopropanol, 
diluted 3:2 with sterile water) was added and left for 20 minutes prior to washing of each well 4 times 
with sterile water. Cells were depicted by Nikon TS100 light microscope and subsequent elution of cel-
lular Oil Red O was done by gently washing of the wells with 1 ml 100% isopropanol. Optical density of 
eluted Oil Red O was measured at 490 nm.
Statistical analyses. Unless indicated otherwise, data values are expressed as Mean ± SEM of three or 
more biological replicates. All experiments were reproduced at least three times. All numerical data pre-
sented was considered to be of normal distribution and statistical differences between mean values were 
evaluated using two-tailed, independent Student’s t-test. Differences of p ≤ 0.05 (indicated*), p ≤ 0.01 
(indicated**) or p ≤ 0.001 (indicated***) were considered significant. GraphPad Prism v5.0 (GraphPad 
Software Inc, La Jolla, CA, USA) was used for statistical calculations and graphical presentation of data.
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